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ABSTRACT 
 
Sexual dysfunction is a common side effect of treatment with antidepressants, 
particularly those with a serotonergic action. The problem has significant implications for 
a patient’s quality of life and their compliance with medication. Given the often long-
term nature of depressive disorders and their treatment this side effect poses a potential 
management challenge and may have serious prognostic implications. 
 
There are currently few evidence-based treatment strategies for the management of 
antidepressant induced sexual dysfunction. This study was conducted to evaluate the 
usefulness of granisetron, a serotonin type-3 receptor antagonist, in the treatment of 
women experiencing sexual dysfunction due to serotonergic antidepressants. 
 
Twelve women with antidepressant induced sexual dysfunction were assigned to receive 
either granisetron (N=5) or placebo (N=7) in a 14-day randomised, double blind, placebo 
controlled drug trial. Two subjects in the granisetron group did not complete the study. 
Each subject’s sexual functioning was assessed at baseline, day 7 and day 14 using both 
the Arizona Sexual Experience Scale and the Feiger Sexual Function and Satisfaction 
Questionnaire. 
 
No statistical differences were measured either at baseline or at endpoint between the 
granisetron and placebo groups. The study did not produce evidence supporting the 
usefulness of granisetron as an adjunctive medication in women with antidepressant 
induced sexual dysfunction. Furthermore, this finding does not suggest a primary role for 
the serotonin type-3 receptor in the pathogenesis of this side effect.
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PREFACE 
 
The problem of antidepressant induced sexual dysfunction cannot be ignored. It is a 
commonly encountered problem in clinical practice, particularly amongst patients being 
treated with serotonergic antidepressants. Practical options for the management of the 
condition are limited and current evidenced based treatment recommendations are largely 
unsatisfactory. 
 
At the time that this project was conceived increased stimulation of serotonin type-2 and 
serotonin type-3 receptors was thought to be a likely mechanism underlying 
antidepressant induced sexual dysfunction. Furthermore, several anecdotal case reports 
and an open label study had suggested that granisetron, a serotonin type-3 receptor 
antagonist, might be useful as a treatment strategy for this condition. 
 
It was therefore natural to further investigate the usefulness of granisetron in more robust 
experimental conditions. It was hoped that the outcome of this study would both validate 
a viable management option and clarify the mechanism underlying antidepressant 
induced sexual dysfunction. 
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1.0 INTRODUCTION 
 
1.1 Normal sexual function 
 
At first glance human sexuality would appear to be amongst the most simple and 
natural aspects of human behaviour. However, when the subject is considered a little 
more carefully it becomes clear that even something as primal as the act of sexual 
intercourse involves a complex interplay of biological and psychological factors. 
Furthermore, this interplay takes place against a rich backdrop of environmental 
influences, cultural meanings and societal norms. In spite of the complexity of human 
sexual behaviour it has really only been during the last fifty years that many of the 
taboos previously shrouding this subject in mystery have been cast aside and a more 
scientific approach applied. 
 
The multiple factors that impact on sexual behaviour are diverse and their interaction 
is indeed complicated. The nature of a person’s interpersonal relationships, current 
life circumstances and stresses, gender identity and sexual orientation, self-esteem, 
emotions and personality structure, cognitive processes, developmental experiences 
across the life-cycle and the process of ageing itself are a few examples (1). Other 
important influences include physical appearance, genetic factors, physical health, the 
presence of psychiatric illness and the use of prescribed medications and drugs of 
abuse (1). It is important to note that normal sexual behaviour may take place in 
relationships of varying levels of commitment, in heterosexual and homosexual 
relationships as well as in the context of self-stimulation. These among many factors 
should be considered when taking a thorough sexual history from a patient. It is, 
however, beyond the scope of this report to discuss them in detail. 
 
When the subject of normal sexual function is reduced to its most basic principles, the 
ability of a human being to successfully complete the act of sexual intercourse 
actually depends on four main factors (2). Firstly, the functional integrity of those 
parts of the nervous system which control the sexual response cycle must be intact. 
Secondly, anatomically normal genital organs are necessary. Thirdly, there must be 
appropriate hormonal stimulation of the genitalia. Fourthly, a psychological 
environment that is conducive to a sexual response must be present. 
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The first part of this chapter will therefore outline the normal human sexual response 
cycle and current understanding of its biological underpinnings. It will also briefly 
discuss some of the psychosocial factors that are relevant to an understanding of 
modern sexual behaviour. The basic facts of physiology, psychology and social 
anthropology as they relate to sexual functioning are an essential foundation of any 
discussion of sexual dysfunction. It should be noted that he separation of the 
biological from the psychosocial is in no way intended to imply that human sexuality 
can be understood as anything but a complex amalgam of both. 
 
Furthermore, sexual dysfunction of any particular cause must always be discussed in 
the context of what constitutes normal or abnormal sexual function in the general 
population. For example, male libido reaches its peak at the end of adolescence and 
then progressively declines (3), whereas women typically reach their peak libido in 
the fourth decade (4). With advancing age there is a gradual decline in interest in sex 
and sexual activity. The frequency of intercourse and masturbation tends to decrease 
and there is an increased incidence of erection and lubrication difficulties. As men 
grow older premature ejaculation becomes less likely and delayed or absent 
ejaculation is a more common complaint. Older women are also increasingly likely to 
experience difficulties with orgasm. However, it is important to stress that sex 
continues to pay an important part in the lives of men and women at least until their 
mid-seventies with little if any decline in enjoyment and satisfaction. 
 
1.1.1 The human sexual response cycle 
 
Masters and Johnson (5) divided the sexual response cycle into four phases: 
excitement, plateau, orgasm and resolution. The Diagnostic and Statistical Manual of 
Mental Disorders, 4th Edition (DSM-IV) (6) also defines a four-phase sexual response 
cycle based on the motivational psycho-physiological model of Masters and Johnson. 
As the DSM-IV classification of sexual dysfunction corresponds with the normal 
phases of the sexual response cycle some discussion of them is warranted. 
 
The first phase is desire, the second is excitement, the third is orgasm and the fourth is 
resolution. Both men and women pass through the same phases of the sexual response 
cycle in the same order. Considerable similarity exists between the genders, but there 
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are also certain differences between them in terms of their patterns of arousal and the 
physiological responses that occur during the completion of normal sexual 
intercourse. The male and female sexual response cycles are not discussed separately 
here although a number of the more important differences are highlighted. 
 
1.1.1.1  The desire phase 
 
This phase refers to the urge people have to engage in sexual activity. It is usually 
internal thoughts, feelings and fantasies that give rise to the physical signs of arousal, 
but it is possible that sexual arousal can precede desire. It seems that desire is 
controlled to some extent by androgens, including testosterone, in both sexes, but 
environmental and psychological factors are also important. In other words, desire is 
influenced by a willingness to engage in sex and also by a biological drive. It is true to 
say that individuals differ widely from one another in the level of their desire, and that 
it is entirely normal for an individual to experience fluctuations in their interest in sex. 
 
1.1.1.2  The arousal phase 
 
During this phase the physical signs of sexual excitement develop. The level of 
physical arousal usually escalates quite quickly. Respiratory rate, heart rate, blood 
pressure and general muscle tension increase in both sexes. The engorgement of blood 
vessels in the genital area produces swelling of the clitoris and labia and vaginal 
lubrication in the female. The uterus also becomes engorged and elevated giving the 
vagina greater length and width. In the male this engorgement is manifest as penile 
erection, scrotal contraction and testicular swelling. It is normal for the level of 
excitement to fluctuate during the arousal phase. It may also fluctuate from one 
occasion to the next and vary from one individual to another. 
 
Physiological arousal continues to build, but it reaches a plateau and does so at a 
slower pace. In women, further vascular engorgement produces tightening of the 
vaginal entrance and a deepening in the colour of the genital area. Other physical 
signs continue to develop and the clitoris withdraws under the clitoral hood. In men, 
there is a further increase in the size of the penis, which deepens in colour and may 
secrete a small amount of pre-ejaculate. When foreplay is prolonged it is normal for 
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arousal to fluctuate in both sexes while it is at the plateau. This fluctuation is more 
noticeable in men as erections may clearly increase and decrease in intensity. In 
woman this is experienced as a change in vaginal lubrication. 
 
1.1.1.3  The orgasm phase 
 
Orgasm occurs when sexual arousal reaches a peak of intensity. This results in a series 
of involuntary rhythmic muscular contractions throughout the pelvic region occurring 
0.8 seconds apart. The female may experience anywhere between two and fifteen 
contractions, which is generally longer than a male orgasm.  The female orgasm may 
last for a few seconds or if stimulation continues then further orgasms may be 
experienced immediately. The quality and intensity of the female orgasm may vary 
according to a variety of factors, including the psychological environment and how 
the orgasm was achieved. 
 
Two separate stages can be identified during the male orgasm. First, emission during 
which the contraction of the vas deferens, seminal vesicles and ejaculating ducts 
places semen at the entrance of the urethra. Second, ejaculation, during which the 
contraction of the penile urethra and surrounding musculature expel seminal fluid 
under pressure. After the initial three or four contractions they become weak and 
irregular. 
 
Respiratory rate, heart rate and blood pressure increase sharply in both sexes during 
this extremely pleasant spasmodic response. The subjective experience of an orgasm 
appears to be very similar for men and woman, but differences do exist. Women may 
experience multiple orgasms, but they are also more likely to engage in intercourse 
without experiencing an orgasm at all. 
 
1.1.1.4  The resolution phase 
 
During the resolution phase the physiological changes produced by sexual arousal 
subside. If orgasm has not occurred the reduction in sexual tension may be relatively 
slow or even experienced as unpleasant. The resolution phase is significantly longer 
for males than females. After an orgasm, males experience a refractory period during 
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which they are largely unresponsive to further stimulation. The length of the 
refractory period varies from a few minutes to a few hours and increases with age. 
 
Two important issues emerge from this account of the sexual response cycle. Firstly, 
although there are obvious anatomical and subtle physiological differences between 
men and woman, there is also much that is common in their sexual responses. 
Secondly, and more importantly with regard to the assessment of sexual dysfunction, 
a certain amount of fluctuation is normal within a single cycle, from cycle to cycle 
and from individual to individual. A temporary reduction in desire or the intensity of 
an orgasm is not necessarily pathological. 
 
1.1.2 The neurobiology of sexual function 
 
The mechanisms underlying the physical manifestations of the human sexual response 
cycle involve a combination of neurological, psychological, vascular and hormonal 
factors that are co-ordinated by the hypothalamus, the limbic system and various 
centres in the cerebral cortex (7). It is generally accepted that sexual function is 
influenced by a variety of neurotransmitters although the exact nature of their 
interaction still awaits clarification. Both dopamine and serotonin certainly play an 
important role. There is also evidence that noradrenaline, acetylcholine and γ-
aminobutyric acid (GABA) are involved as well. Although the role of a variety of 
other chemicals remains to be clarified research has also implicated oxytocin, 
arginine-vasopressin, angiotensin II, growth hormone releasing hormone, substance P, 
neuropeptide Y and cholecystokinin-8 (8). The interaction of the endocrine system via 
the steroid sex hormones and the neurological system including both its central and 
peripheral components underlies the normal human sexual response. 
 
Centrally, it appears that dopamine and serotonin via the hypothalamus and its 
associated limbic structures modulate testosterone function, at least in part. 
Significantly, decreased levels of bio-available testosterone may result in symptoms 
such as a diminished sense of well being or a low mood, persistent unexplained 
fatigue and changes to sexual function that include decreased libido, reduced sexual 
receptivity and diminished sexual pleasure (9). 
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Peripherally, effects on sexual functioning appear to be even more complicated. 
Oestrogen, testosterone and progestin released by the ovaries or adrenal glands 
maintain genital structure and function (10). They also influence the availability and 
function of each other. For example, increasing levels of oestrogen may lead to an 
increase of sex hormone binding globulin. This binds to testosterone reducing the 
amount of free testosterone that is available. Furthermore, progestin has anti-
oestrogen effects. Oestrogen also influences nerve transmission and sensory 
thresholds at a peripheral level (11). 
 
The exact relationship between neurological and endocrine processes and 
neurotransmitter or receptor activity is not properly understood. However, the 
following overview is an attempt to summarise current knowledge regarding these 
central and peripheral processes with reference to the phases of the sexual response 
cycle that are particularly relevant to this report: desire, excitement and orgasm. An 
attempt will also be made to clarify current thinking on the relative roles of the 
serotonin type-2 (5HT2) and type-3 (5HT3) receptors. 
 
1.1.2.1  The desire phase 
 
The central nervous system is clearly involved in this phase of the sexual response 
cycle. Dopamine is thought to have central effects on sexual functioning and to 
enhance sexual desire. The mesolimbic system is associated with the development of 
interest in sexual activity and dopamine appears to be required in this area for the 
maintenance of sexual interest (12). The inhibition of dopamine release may impair 
libido and erection (13). Experimentally, potent selective antagonism of serotonin re-
uptake appears to reduce dopamine activity in the mesolimbic system. This effect is 
probably mediated by 5HT2 receptors (12). In animal models, when serotonin type-1A 
(5HT1A) receptors are stimulated using agonists such as buspirone, sexual activity 
seems to be facilitated. The 5HT1A receptor, coupled to other serotonin receptors, may 
well play a significant role in alterations in sexual interest (14). 
 
Good evidence exists that the steroid sex hormones play an important role in the 
development of sexual desire. Oestrogen and the development of desire seem to be 
linked in women and progesterone may possibly mediate a female’s receptivity to the 
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approaches of her partner (15). Testosterone appears to be the most important sex 
steroid, but attempts to relate circulating levels of testosterone to sexual desire have 
been inconsistent (16). The relationship between testosterone, dopamine and 
serotonin, and the hypothalamus and associated limbic structures is fairly well 
described in males. However, the interaction is somewhat less conclusive in females. 
This may be a reflection of the impact of psychosocial factors on sexual desire (17). 
Oxytocin seems to be related to changes across the menstrual cycle and it possibly has 
a role in enhancing sexual receptivity (18). There is convincing evidence that 
increased prolactin causes sexual dysfunction as it depresses sexual activity in the 
desire, arousal and orgasm phase of the sexual response cycle. Furthermore, elevated 
plasma prolactin reduces testosterone levels (19). 
 
There has been some speculation that pheromones play a role in the sphere of human 
desire and attraction. A pheromone is a chemical substance that is secreted by one 
animal to influence the behaviour of another animal. These chemicals are most 
commonly detected by the animal’s sense of smell and are thought to influence both 
sexual and other behaviours. The role of pheromones as mediators of human sexual 
desire is controversial. Some evidence exists to suggest that pheromones may be 
responsible for the synchronisation of menstrual cycles and ovulation that occurs 
between women when they live together (20). However, although the role of 
pheromones has been demonstrated in animal models, there is no convincing evidence 
that they exert any effect on sexual desire in humans or the higher primates (21). 
 
1.1.2.2  The arousal phase 
 
Both the central and peripheral nervous systems mediate sexual excitement. This 
phase of the sexual response cycle is mediated in the mesolimbic system at least 
partially by dopamine. Dopamine appears to enhance a person’s subjective sense of 
excitement (12). Sexual arousal is likely to be related to general reward and pleasure 
seeking activity, and it certainly seems that dopamine also enhances a person’s wish 
to continue sexual activity once sexual stimulation has been initiated. Inhibition of 
dopamine release may impair libido and erection (13). These dopaminergic effects 
can be inhibited by potent selective serotonin re-uptake antagonism (14). Although 
serotoninergic stimulation appears to generally inhibit sexual function it is thought to 
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predominantly affect sexual desire, ejaculation and orgasm (7). There is convincing 
evidence that noradrenaline is involved centrally in the arousal phase (22). Increased 
serotonergic neurotransmission in the central nervous system can diminish both the 
effects of dopamine (23) and noradrenaline on sexual functioning (24). 
 
Peripherally, sympathetic and parasympathetic activity mediates the spinal reflexes 
associated with erection and clitoral engorgement. The parasympathetic nervous 
system promotes penile and clitoral erection, whereas sympathetic activity mainly 
moderates arousal (25). This process is mediated in turn by serotonin and several 
other neurotransmitters that impact on sympathetic and parasympathetic tone (12). 
Potent selective serotonin re-uptake antagonism may result in inhibition of these 
important peripheral spinal reflexes (14, 22). It is worth noting the role of 
acetylcholine as a neurotransmitter in spinal nerves. Cholinergic nerves innervate 
vascular smooth muscle in the vagina and may be associated with vaginal 
engorgement during sexual arousal (26). Although its role in sexual intercourse is not 
clear noradrenergic activity seems to have a close relationship to the onset and 
maintenance of copulatory behaviour in rats (27). In peripheral tissues serotonin 
appears to play a role in the initiation of sexual arousal by way of its effects on 
vascular tone and blood flow. However, serotonin may also interfere with arousal via 
its effects on sensation, the reduction of adrenergic effects and the inhibition of nitric 
oxide synthase (28). 
 
Nitric oxide has been implicated in the modulation of sexual arousal at a peripheral 
level because it mediates the vascular changes required for pelvic engorgement and 
erection (29). This is demonstrated by sildenafil, a potent phosphodiesterase inhibitor, 
which augments nitric oxide resulting in smooth muscle relaxation and the flow of 
blood to the genitalia. Vascular congestion of the clitoris seems to be positively 
mediated by nitric oxide (30) and vasoactive intestinal polypeptide (31) once sexual 
stimulation begins. Vasoactive intestinal polypeptide may mediate autonomic effects 
on pelvic blood flow during arousal (32). 
 
In the central nervous system serotonin acts as a neurotransmitter but in the peripheral 
system it has vasoconstrictor and vasodilator effects that impact on sexual arousal 
(28). The presence of adequate levels of oestrogen (33) and testosterone appears to be 
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required in order for nitric oxide to initiate the vascular congestion that occurs with 
sexual stimulation (34). Certainly, testosterone seems to be involved in the initiation 
of sexual activity. In women oestrogen appears to be particularly important in the 
arousal phase. The declining oestrogen levels associated with menopause may lead to 
vaginal atrophy and subsequently difficulty with vascular congestion and vaginal 
lubrication. Prolactin also influences the sexual arousal phase with increasing levels 
of prolactin having a negative effect on arousal and the subsequent phases of sexual 
functioning (35). 
 
Given adequate sex steroids, including testosterone in men and oestrogen in females, 
the potential physiological mechanisms mediating sexual arousal include central 
dopamine stimulation, the modulation of cholinergic-noradrenergic balance, 
peripheral α1-adrenergic receptor agonism and the presence of nitric oxide (35). 
 
1.1.2.3  The orgasm phase 
 
The central nervous system is likely to have some impact on this phase of the sexual 
response cycle. Dopamine appears to enhance sexual function generally, and this 
effect is in all likelihood modulated centrally by serotonin. However, orgasm and 
ejaculation appear to be primarily mediated at the spinal level. The parasympathetic 
nervous system mediates orgasm and ejaculation, whereas the sympathetic nervous 
system has a moderating influence on this phase (25). 
 
Sympathetic and parasympathetic tone is important in mediating orgasm and 
ejaculation. This is at least partly dependent upon the activity of noradrenaline and 
dopamine that are modulated by serotonin at 5HT2 receptors (14, 36). Potent selective 
serotonin re-uptake inhibition is thought to result in a 5HT2 receptor mediated 
decrease in noradrenaline and dopamine activity required for orgasm and ejaculation. 
Inhibition of orgasm may occur with serotonergic activation and this is likely to be 
due to 5HT2 receptor stimulation (37) with α-adrenergic receptor antagonism (22). 
Antagonism of peripheral α-adrenergic and cholinergic receptors in the genitourinary 
tract impairs sexual function (38). Drugs with potent antagonism of cholinergic and 
α1-adrenergic receptors can interfere significantly with the sexual response cycle (39). 
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Increased serotonergic neurotransmission is associated with a subjective sense of 
diminished sensation in the genital area (36). Nociceptive sensation is partially 
modulated by serotonin and this may partially explain the difficulties with orgasm that 
are associated with diminished sexual sensation. However, it is not clear that the 
sensations of pain and pleasure involve similar pathways. 
 
In peripheral tissues serotonin may potentially play a role in orgasm by facilitating 
uterine contractions. It may also, however, interfere with orgasm by stimulation of 
5HT2 receptors (37). The current understanding of this mechanism is rudimentary, but 
it may well be related to oxytocin (40). Oxytocin is associated with pelvic 
contractions and increased systolic blood pressure at the time of orgasm. 
 
The complex neurobiological interactions that influence sexual function are still 
poorly understood and any attempt to represent them schematically is likely to be an 
oversimplification. However, the central influences on sexual function are illustrated 
in Figure 1.1 (35) and the peripheral influences in Figure 1.2 (35).  
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Figure 1.2 Peripheral influences on sexual function (“+” indicates a positive 
effect, “–” indicates a negative effect, “?” indicates that the effect is 
unknown)  
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1.1.2.4  The role of the serotonin type-3 receptor 
 
A reasonable body of data exists concerning the impact of serotonin type-1 (5HT1) 
and 5HT2 receptors on mammalian sexual activity. The sex of the animal and the 
subtype of serotonin receptor that is activated appear to have a significant influence 
on sexual activity in experimental settings. In female rats 5HT1A receptor activity 
inhibits lordosis whereas this marker of animal sexual behaviour is facilitated by 
serotonin type-1B (5HT1B) and 5HT2 receptor activation. Conversely, activation of the 
5HT1A receptor enhances male rat copulation and activation of 5HT1B and 5HT2 
receptors inhibits this behaviour (41). In animal models this inhibitory effect of 
serotonin is mediated by post-synaptic 5HT2 receptors, and serotonin type-2C (5HT2C) 
receptor subtype agonists such as m-chlorophenylpiperazine provoke sexual 
excitement in experimental animals (7). There is, however, comparably little known 
about the role of the 5HT3 receptor. The majority of information which exists is 
derived from the clinical use of pharmacological agents with differing 5HT3 receptor 
activity.  
 
The identification of 5HT3 receptors in the brain and the synthesis of relatively 
selective 5HT3 receptor antagonists have stimulated interest in activity at this 
receptor. The existence of 5HT3 binding sites in areas fundamentally involved in 
mediating sexual behaviour such as the hypothalamus suggest that 5HT3 receptor 
activity may be influential (42). There have been reports of 5HT3 receptor antagonists 
attenuating the effects of increased dopamine activity in mesolimbic structures (43). 
They may also inhibit certain opiate induced behaviours. 
 
High doses of selective 5HT3 receptor antagonists have both enhanced and failed to 
enhance lordosis in female rats. Granisetron, ondansetron and the experimental 5HT3 
receptor antagonist MDL 72222 have been shown to facilitate lordosis in sexually 
disinterested female rats, though in male rats another experimental agent ICS 205-930 
failed to affect sexual activity (43).  
 
Endogenous opioids may play a role in the regulation of sexual behaviour (44) and 
independently of their direct effects it seems that 5HT3 receptor antagonists may 
modulate sexual behaviour via their interactions with the opioids. Morphine appears 
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to increase hypothalamic 5HT3 activity (45) and inhibits copulation in rat models (44). 
There is preliminary data to suggest that ICS 205-930 may attenuate morphine-
induced inhibition of male copulation (41). These findings are consistent with the 
possibility that agents with 5HT3 receptor activity may antagonise the effects of 
opioids on sexual behaviour. 
 
However, not all data supports a role for the 5HT3 receptor (43). The effects of 
selective 5HT3 antagonists MDL 72222, ondansetron and ICS 205-930 on the sexual 
activity of female rats were examined and male rats were investigated using 
ondansetron and granisetron. The study found that none of these agents had any affect 
on female or male copulation. The conclusion was that 5HT3 receptors appeared to 
contribute little to the modulation of sexual activity. Furthermore, although morphine 
did inhibit copulation in this study, ondansetron and ICS 205-930 failed to reverse this 
effect. The influence of the 5HT3 receptor on opioid induced inhibition of sexual 
activity is therefore also doubtful. 
 
In summary, the relative role of the 5HT3 receptor as a mediator of sexual function 
remains controversial. It appears that the 5HT2 receptor plays a more important role in 
this regard. 
 
1.1.3 Psychosocial aspects of sexuality 
 
Sexual activity is essential for the survival of a species, but it is not, however, an 
essential requirement for the survival of the individual (46). Human sexuality has 
come to be associated with values and meanings that have less to do with our survival 
as a species than with our ability to function in a complex modern society. A 
complicated network of psychological and social factors influence sexual behaviour, 
and by the same token sexual behaviour has important consequences for 
psychological and social well being. 
 
Masters and Johnson broke new ground in detailing the physical features of the sexual 
response cycle (5), but their research also demonstrated that many sexual problems 
are caused by psychological factors. Although modern society is in many ways 
obsessed with sex, and although sex is an important motivating force that generates 
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some of people’s most powerful emotions, misconceptions about sexuality are 
common. Generally, animals appear to execute the sex act with a minimum of 
difficulty, but the values and meanings that humans imbue sexuality with makes their 
sexual relations considerably more complicated (2). 
 
The term “psychosexuality” is used to describe personality development and 
functioning as they are affected by an individual’s sexuality (1). Sexuality and 
personality are so entwined that it is impossible to speak of sexuality separately. An 
individual’s sexuality depends on four interrelated factors. Firstly, sexual identity or 
the person’s biological sexual characteristics as defined by chromosomes, external 
and internal genitalia, hormonal composition, gonads and secondary sex 
characteristics. Secondly, gender identity or the firm conviction that develops in early 
childhood of being either male or female. Thirdly, sexual orientation or terms like 
heterosexual, homosexual and bisexual that are used to describe a person’s sexual 
impulses. Fourthly, sexual behaviour which encompasses a wide range of sexual 
rituals and practices. These four factors operate throughout the life cycle and have 
important effects an individual’s personality growth, development and functioning. 
 
The sexual response of both males and females is sensitive to the situation in which 
they find themselves. This situation is comprised of both their current psychological 
state and their environment. Psychological factors may be far more important in 
sexual functioning than poorly developed genitalia, hormone deficiency or 
neurological disturbances (47). Psychological factors include a person’s cultural and 
religious background, their parents’ attitudes towards sex and communication on the 
subject and parental reactions to a child’s developing sexuality. Childhood fantasies 
and experiences, reactions and experiences during adolescence and knowledge of sex 
organs and their function are also important. Other psychological determinants 
include previous sexual experiences, self-esteem and the individual’s sense of 
sexuality, masturbation fantasies, expectations of a relationship and attitudes towards 
contraception, pregnancy and sexually transmitted disease. This sets the stage for the 
physiological chain of events that make up the sexual response cycle. 
 
There is some value in looking at the factors that are considered to promote rewarding 
sexual relationships (48, 49, 50, 51). That they relate fairly specifically to 
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heterosexual couples in a relationship based on sincere commitment and affection is 
relevant given the focus of this report. Firstly, patients and their partners need 
accurate information or, in other words, sex education. This relates primarily to 
knowledge about sex organs and the way in which they function, the human sexual 
response cycle and the normal fluctuations that occur in sexual desire and 
performance, reproductive physiology, contraception and the psychosocial 
determinants of sexual function. Secondly, sexual values and feelings of guilt. Each 
partner brings to the relationship an at best subtly different social history and set of 
experiences which impact greatly on the health of their sex life. Thirdly, 
communication is important. In an area of human relationships that is so emotionally 
charged the potential for misunderstanding is great and likely to have far reaching 
implications. Therefore, effective communication regarding differing interpretations 
of sexual behaviour and expectations of sexual activity is extremely important. 
Fourthly, perhaps particularly in a long-term relationship the value of sexual fantasy 
should not be denied or underestimated. Finally, it is vital that both partners have 
realistic expectations of each other and the sexual relationship they are involved in. It 
goes without saying that these factors operate against the background of trust that 
should be a part of any sincere, committed relationship. 
 
Sexual activity does not always take place in the context of a stable long-term 
relationship. It does, however, always have potential implications of one kind or 
another and never occurs in complete isolation. Burt & Brower (47) proposed a set of 
criteria that are can be generalised to most sexual relationships and form the basis for 
a modern code of sexual ethics that respect human dignity. Firstly, both partners must 
be certain that they are free of sexually transmitted disease. Secondly, both partners 
must recognise their responsibility to love and care for the offspring that may result 
from sexual intercourse. Thirdly, both partners should have some notion of direction 
and their goals in life and where sexual activity with all its implications fits in to this. 
Fourthly, one person must not exploit another; the sexual encounter should be an 
experience of love or at least mutual respect. 
 
The period of rapid social change that took place in the second half of the last century 
and is often called the sexual revolution has significantly affected the nature of 
relationships between men and women, the structure of the family and the role of 
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women in society. In many parts of the world large families are no longer the social or 
economic asset they once were (2). In first world societies children are expensive, 
their education is often prolonged and they do not offer the security to their parents 
that they did previously. In addition, societal pressure on people to form lifelong 
bonds, marry and have children has lessened. Many men no longer feel that carrying 
on the family line is of great importance and larger numbers of women are choosing 
not to marry and to delay having children until later in their reproductive life. As a 
result, birth rates have fallen throughout the developed world and a woman’s status as 
the child-bearer has declined. It is true that to a certain extent societal pressure still 
defines a woman’s role as a wife and mother, but society is also placing increasing 
attention on the value of a woman’s economic and sexual emancipation. 
 
There is growing emphasis on sex and personal relationships as a basic source of 
happiness and fulfilment (2). Restrictive attitudes to sex and sexual expression are 
diminishing and people have had to develop new approaches and new standards. 
There is an acknowledgement of the individual’s right to determine the manner in 
which they express their sexuality. As society has shifted towards increasingly 
valuing individual responsibility and respect of a person’s right to free choice, sexual 
activity is no longer a set pattern of behaviour. Instead, it is a form of intimate 
physical contact for pleasure that can take place in a variety of contexts. Ideally, 
consenting partners recognise the implications which sexual activity has for the nature 
of their relationship and the risks of pregnancy and sexually transmitted diseases. The 
tendency for women to be more financially and emotionally independent has been 
accompanied by a trend towards more aggressive sexual behaviour of the kind that 
has traditionally been associated with masculinity. In the context of sexual 
relationships women are increasing likely to demand equality rather than assume a 
passive role. 
 
In conclusion, human sexuality is something more than physical sex and something 
less than every aspect of behaviour directed towards attaining pleasure as espoused by 
psychoanalytic theory. Sexual behaviour is an immeasurably variable and constantly 
changing concept. Any investigation into the subject must take cognisance of this 
reality. It is also important to note that much of our understanding of human sexuality 
is based on patterns of behaviour observed in relatively homogenous western 
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countries. This does not adequately address the different beliefs and attitudes that 
exist towards sexual behaviour in other cultures. 
 
1.2 Sexual dysfunction 
 
Terms such as “sexual complaint”, “sexual dysfunction” and “sexual disorder” are 
often used interchangeably to describe sexual difficulties of various kinds. For the 
purposes of this report it is useful to define these terms a little more specifically as 
they provide a basis for the discussions that follow (35). A sexual complaint is an 
expression of discontent or pain that refers specifically to problems of a sexual nature. 
A sexual dysfunction is disturbance in sexual functioning that involves one or more 
phases of the sexual response cycle or somatic pain associated with sexual activity. A 
sexual disorder is a sexual dysfunction that meets DSM-IV criteria for a specific 
sexual disorder. According to DSM-IV diagnostic criteria a sexual disorder must 
include significant dysfunction and marked distress (6). General terms such as “sexual 
difficulty” and “sexual problem” refer non-specifically to all of the above. 
 
In keeping with the title of this report an emphasis will be placed on sexual 
dysfunction in women. A discussion of antidepressant induced sexual dysfunction and 
its management is impossible without some understanding of sexual dysfunction 
generally. 
 
1.2.1 Epidemiology 
 
In spite of the fact that reliable epidemiological data is lacking, sexual dysfunction 
and sexual disorders are undoubtedly common in the general population. The 
sensitive nature of sexual complaints makes patients reluctant to report them and it is 
probably also true that clinicians avoid asking about sexual problems or even taking a 
sexual history for a similar reason (52). There is evidence that the rates at which 
sexual dysfunction are reported vary significantly depending on the method of data 
collection selected. The lowest prevalence rates are found with spontaneous self-
reporting. Higher prevalence rates are found when confidential questionnaires are 
used. The highest rates of sexual dysfunction are reported when people are questioned 
directly about their symptoms (8, 53). This issue should be borne in mind when 
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selecting an appropriate information-gathering technique for research purposes. It is 
also not surprising that epidemiological estimates of the prevalence of sexual 
problems vary widely. 
 
An important 1978 study suggested that approximately half of all couples were 
troubled by some degree of sexual difficulty (54). In the 1992 National Health and 
Social Life Survey in the United States 43% of women and 31% of men who had been 
sexually active in the previous year complained of sexual problems (55). The 
women’s most common complaints were of reduced sexual desire (33%), impaired 
lubrication (19%) and difficulty attaining orgasm (24%). It also appeared that the 
women’s sexual problems decreased as their age increased, except in the case of the 
impaired lubrication and arousal difficulties associated with menopause. Younger 
women reported more problems with sexual desire and difficulty achieving orgasm 
than older ones. Sexual difficulties in this survey were also associated with poor 
physical and emotional health, negative experiences of sexual relationships, sexual 
trauma, declining social status and a negative overall sense of wellbeing. A postal 
survey conducted recently in England reported similar rates of sexual problems (56) 
and found an association between psychosocial stresses such as marital conflict and 
problems with arousal, orgasm and sexual pleasure (57). More than half (52%) of 
respondents to this survey indicated that they would like to receive professional help 
for a sexual problem, though only 10% had ever received any such help. 
 
The prevalence of sexual problems obviously varies according to the population that 
is being surveyed. In a study of patients attending a family practice centre 75% of the 
sample reported sexual problems of one kind or another (58). Furthermore, prevalence 
is likely to vary depending on the criteria used to define sexual dysfunction. Many 
surveys are based on loosely defined terms or criteria other than those defined by the 
DSM-IV. A 1998 study using DSM-IV criteria reported sexual dysfunction in 26% of 
normal subjects (59). This is probably one of the most reasonable estimates of the 
prevalence of sexual dysfunction that exists in current literature. 
 
When it is relevant and available epidemiological data that meets DSM-IV criteria 
will be provided for the individual sexual disorders discussed below. However, it 
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appears that overall the most common sexual problems experienced by women are 
loss of sexual desire, difficulties with orgasm and vaginismus. 
 
1.2.2 Classification and clinical presentation 
 
Sexual disorders are grouped into three broad categories according to DSM-IV: the 
sexual dysfunctions, the paraphilias and the gender identity disorders (6). The sexual 
dysfunction classification is in turn subdivided into sexual desire disorders, sexual 
arousal disorders, orgasmic disorders, sexual pain disorders, sexual disorders due to a 
medical condition or due to the effects of a substance, and sexual dysfunction not 
otherwise specified. This subdivision is obviously derived from the various phases of 
the human sexual response cycle. Resolution is a passive phase and is not associated 
with any known sexual dysfunction. 
 
Sexual disorders should not be diagnosed if they are caused by another psychiatric 
condition. For example, the loss of libido associated with major depressive episodes 
should not be classified as a disorder. This is not to suggest that other psychiatric 
disorders and their treatment do not produce sexual dysfunction. Furthermore, the 
onset of a sexual disorder may precede that of a psychiatric condition and therefore 
occur concurrently with it. 
 
1.2.2.1  Sexual desire disorders 
 
Hypoactive sexual desire disorder 
 
A 1986 review of 22 general population surveys found a higher prevalence of 
hypoactive sexual desire disorder in females compared to males (females 1% to 35%, 
males 1% to 15%) (60). Certainly, this appears to be the most common sexual 
disorder experienced by women. Overall estimates of its prevalence vary from 5% to 
46% in the general population and from 10% to 46% in primary care settings (61). In 
addition, comordity is common. Approximately 40% of women with hypoactive 
sexual desire disorder appear to also have secondary diagnoses of arousal or orgasm 
disorders (62). The disorder presents with a lack sexual fantasy and desire for sexual 
activity (6). This disorder may have a primary cause, but frequently it is related to 
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temporary stresses or such practical issues as a lack of privacy or the opportunity to 
have sex. A relationship problem or interpersonal difficulty frequently lies at the root 
of hypoactive sexual desire disorder. 
 
Sexual aversion disorder 
 
Epidemiological data on this condition are lacking. Sexual aversion disorder differs 
from hypoactive sexual desire disorder in that there is a distinct aversion to genital 
sexual contact with a partner (6). Sexual intercourse is actively avoided and can 
develop into an aversion to other non-genital sexual contact. The onset of sexual 
activity can precipitate considerable anxiety, and it is thought that a high proportion of 
people with this disorder have experienced sexual trauma (63). 
 
1.2.2.2  Sexual arousal disorders 
 
Male erectile disorder 
 
This disorder which is also known as erectile dysfunction or impotence has been 
reported in up to 40% of men at age 40 years and 70% at age 70 years (64). The 
incidence obviously increases with advancing age. Male erectile disorder presents 
with the inability to attain an adequate erection or to maintain it until the completion 
of sexual activity (6). It may be either a lifelong or an acquired condition and its 
causes may be organic, psychological or a combination of both (1). 
 
Female sexual arousal disorder 
 
Definitive epidemiological data is lacking but the lifetime prevalence of this disorder 
has been reported as being around 6% in a sample of the general population aged 
between 55 and 57 years (65) and up to 21% of women attending a premenstrual 
syndrome clinic (66). Female sexual arousal disorder manifests as an inability to 
adequately attain and maintain the lubrication and engorgement associated with 
sexual excitement (1). The condition may for obvious reasons rapidly develop into 
other sexual disorders including problems with desire and pain during intercourse. 
Female sexual arousal disorder appears to be more common in women involved in 
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long-term sexual relationships, though in reality a number of other psychosocial 
factors have been associated with disordered sexual arousal. 
 
1.2.2.3  Orgasmic disorders 
 
Female orgasmic disorder 
 
Although inhibited orgasm has been reported in between 5% and 30% of females 
(60), the lifetime prevalence of this disorder in the general population sample aged 
between 55 and 57 years was only 4% (65). It was found to be about 5% in the survey 
at a premenstrual syndrome clinic (66). In clinical settings it appears that problems 
with orgasm are far more common than epidemiological figures suggest. This 
probably has something to do with the under reporting of the condition. Certainly, 
difficulty achieving orgasm is a significantly more common problem than female 
orgasmic disorder as defined by DSM-IV criteria. Female orgasmic disorder presents 
as a delay in or the absence of orgasm after a normal sexual excitement phase (6). The 
diagnosis of the disorder should be made in the context of an individual woman’s 
capacity to achieve orgasm. This is likely to be influenced by factors such as her age, 
degree of sexual experience and the extent of sexual stimulation. A number of 
biological and psychosocial factors have been associated with the development of this 
disorder. 
 
Male orgasmic disorder 
 
Male orgasmic disorder occurs when a man achieves ejaculation during intercourse 
only with great difficulty or not at all. Its prevalence rate in the general population is 
probably around 5% (60). 
 
Premature ejaculation 
 
Premature ejaculation is a common problem amongst men. It presents with persistent 
or recurrent ejaculation with minimal stimulation before adequate vaginal penetration 
or before the person wishes it (6). Again, the diagnosis of this disorder should be 
made only in the context of factors such as age, the novelty of the sexual partner or 
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situation, the frequency of recent sexual activity and the duration of the excitement 
phase. Females are able to have multiple orgasms within a relatively short period of 
time and therefore there is no disorder in women that is the equivalent of premature 
ejaculation (63). 
 
1.2.2.4  Sexual pain disorders 
 
Dyspareunia 
 
Dyspareunia refers to the experience of genital pain associated with sexual intercourse 
in either men or women (6). The anticipation of further pain frequently gives rise to 
an avoidance of sexual activity and dysfunction in other phases of the sexual response 
cycle, particularly vaginismus. 
 
Vaginismus 
 
Vaginismus is characterised by the involuntary spasm of the musculature of the outer 
third of the vagina (6). This interferes with sexual intercourse. Not surprisingly, 
avoidance of sexual activity and other sexual dysfunctions such as dyspareunia 
frequently develop. 
 
1.2.2.5  Sexual dysfunctions due to a general medical condition 
 
A variety of medical conditions have been associated with sexual dysfunction. Rates 
of sexual disorders are higher in medically ill patients (67% versus 25%) and are 
particularly common in those with endocrine and neurological disorders (35). 
Increasing problems with sexual function may indicate a progression or inadequate 
treatment of underlying medical conditions. 
 
1.2.2.6  Substance-induced sexual dysfunction 
 
The DSM-IV diagnostic criteria for substance induced sexual dysfunction are 
included in Table 1.1 (6). Depending on the nature of the substance the dysfunction 
may involve impaired desire, arousal orgasm or pain, or a combination of these.  
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Table 1.1 Diagnostic criteria for substance-induced sexual dysfunction 
 
 
A. Clinically significant sexual dysfunction that results in marked distress or 
interpersonal difficulty predominates in the clinical picture. 
 
B. There is evidence from the history, physical examination, or laboratory 
findings that the sexual dysfunction is fully explained by substance use as 
manifested by either (1) or (2): 
(1) the symptoms in Criterion A developed during, or within a month of , 
substance intoxication 
(2) medication use is aetiologically related to the disturbance 
 
C. The disturbance is not better accounted for by a sexual dysfunction that is not 
substance induced. Evidence that the symptoms are better accounted for by a 
sexual dysfunction that is not substance induced might include the following: 
• the symptoms precede the onset of the substance (or medication) use or 
dependence 
• the symptoms persist for a substantial period of time (eg. about a month) 
after the cessation of intoxication, or are substantially in excess of what 
would be expected given the type or amount of the substance used or the 
duration of use 
• other evidence that suggests the existence an independent non-substance-
induced sexual dysfunction (eg. a history of recurrent non-substance-
related episodes) 
 
 Note: This diagnosis should be made instead of a diagnosis of substance 
intoxication only when the sexual dysfunction is in excess of that usually 
associated with the intoxication syndrome and when the dysfunction is 
sufficiently severe to warrant independent clinical attention. 
 
 Code: [Specific substance]-induced sexual dysfunction. 
(Alcohol; amphetamine or amphetamine-like substance; cocaine; opioid; 
sedative, hypnotic or anxiolytic; other or unknown substance.) 
 
 Specify if: 
• with impaired desire 
• with impaired arousal 
• with impaired orgasm 
• with sexual pain 
 
 Specify if: 
• with onset during intoxication if the criteria are met for intoxication with 
the substance and the symptoms develop during the intoxication syndrome 
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Sexual dysfunction has been linked to a variety of pharmacological agents. 
Medications used to treat general medical conditions such as digoxin and other 
cardiovascular agents, antihypertensives, antihistamines, analgesics and steroids, 
hormonal preparations and the oral contraceptive pill, antineoplastic agents and 
hypolipidemic drugs have all been implicated (67). Psychotropic medications, 
including antidepressants, antipsychotics, lithium and sedative or hypnotic agents 
have also been convincingly implicated. Drugs of abuse including prescription and 
over the counter medication, alcohol, nicotine and illicit substances may all impact on 
sexual function. It is important to note that when a substance causes sexual problems 
this represents a sexual dysfunction rather than a disorder. In order to make this 
diagnosis a temporal relationship should exist between the onset of sexual side effects 
and the commencement of a medication known to be associated with sexual 
dysfunction. 
 
1.2.2.7  Sexual dysfunctions not otherwise specified 
 
This DSM-IV category is for sexual dysfunctions that do not meet the criteria for one 
of the above specific sexual dysfunctions (6). Of particular relevance to this report are 
the complaints of diminished genital sensation and loss of intensity of arousal or 
orgasm (68). These problems are not currently considered sexual disorders although 
they may well represent sexual dysfunction. 
 
1.2.3 Aetiology 
 
Sexual dysfunction may be due to the organic, pharmacological, psychosocial and 
situational factors outlined above. When a particular sexual dysfunction is due to 
predominantly psychological factors it is considered a primary sexual disorder. 
Prolonged abstinence from sex may in itself suppress sexual desire. Fears of 
becoming pregnant, rejection by partner or any of the psychosocial factors outlined 
previously may be significant. Sexual disorders are often caused by a combination of 
factors. For example, it is unusual for sexual dysfunction due to a physical cause to 
manifest without the patient being on a medication and experiencing some degree of 
psychosocial stress at the same time. There is some evidence that chronic stress and 
anxiety can effect the neurobiological factors outlined previously. Difficulties in the 
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later phases of the sexual response cycle (arousal and orgasm) can have an indirect 
effect on libido, in which case the primary phase disturbance should be addressed. 
 
1.2.4 Management 
 
A detailed discussion of the general management of sexual dysfunction is beyond the 
scope of this report. A detailed account of the management of antidepressant induced 
sexual dysfunction (AISD) will be given subsequently. In terms of general principles, 
when there is an underlying medical cause this problem should be addressed. If the 
cause is a prescribed medication or a drug of abuse then this should be the focus of 
intervention. For the vast majority of primary sexual dysfunctions the main 
intervention is likely to be psychotherapeutic. The emphasis of therapy should be on 
the couple rather than the individual presenting with the problem.  Principles include 
education, communication, and rectifying dysfunctional attitudes towards sex. This 
may be accompanied by behavioural techniques often set as homework. There are a 
number of physical interventions that can be used for the problem, and the availability 
of peripherally acting vasodilator agents has for better or worse revolutionised the 
treatment of this problem. Hormone replacement therapy may be useful in post-
menopausal women complaining of sexual dysfunction (69). 
 
In conclusion, consideration should be given to whether a person has a sexual 
complaint, a sexual dysfunction or a sexual disorder (35). A psychosocial 
intervention, sex education, or watchful waiting may best address a sexual complaint. 
Sexual dysfunction may respond to appropriate treatment of the underlying medical or 
psychiatric condition. Reducing substances or adding the appropriate antidote, or 
simply education and psychotherapy to improve sexual responsiveness may be useful. 
Minimising the number of medications, reducing doses when appropriate, substituting 
medication while treating underlying condition can lead to improvement. Treatment 
of primary sexual disorders may include psychotherapy especially if there is a history 
of trauma. Pharmacotherapy may play a role for some, but at this time there are no 
registered treatments for women. 
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1.3 Sexual dysfunction and depression 
 
Although the effect of mood and anxiety on sexual function has long been recognised 
little research has been undertaken on the subject until fairly recently. Most of the 
rather limited information that is available has resulted from incidental findings in 
studies with different aims. Unfortunately the recent surge in interest in AISD has not 
been accompanied by a corresponding increase in the investigation of the sexual 
dysfunction caused by depressive illness (70). 
 
1.3.1 Epidemiology 
 
Sexual dysfunction is a common symptom of depression. It has been reported that 
between 40% and 75% of depressed patients experience the problem in one form or 
another (70). A 1998 study found that sexual dysfunction was present in 45% of 
untreated depressed patients (59). A more recent evaluation of 4557 depressed 
patients in France confirmed that the prevalence sexual dysfunction is high in this 
group (69%) and concluded that sexual problems amongst these patients were often 
not optimally treated (71). 
 
Between 40% and 50% of people with depression reported diminished libido and 
difficulties with sexual arousal in the month before a diagnosis of depression was 
made in one study (72). In the same study it was found that only 15% to 20% of 
depressed people experienced difficulties with orgasm before treatment was 
commenced. Decreased libido has been reported in up to 75% of depressed patients. 
Its prevalence is similar across cultures and greater in younger patients with 
depression. An improvement in libido seems to correlate with an improvement in 
mood along with the other somatic symptoms of depression (70). 
 
It is also worth noting that depression has been reported in about 30% of patients 
seeking treatment for a variety of sexual disorders (73). A lifetime history of 
depression has been found in 72% of physically healthy subjects with hypoactive 
sexual desire disorder compared to 29% of normal controls (74). 
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1.3.2 Classification and clinical presentation 
 
Major depressive disorder is a severe and frequently chronic illness that places a 
significant strain on relationships in its own right. Sexual difficulties are often not the 
priority of the patient and the clinician during the acute stage of a severe depressive 
episode. Sexual dysfunction is much more likely to be a focus of attention during the 
recovery or maintenance phase of a depressive illness or when the condition is of mild 
to moderate severity. Sexual dysfunction may occasionally be the only presenting 
complaint in a depressive episode (73). Occasionally depressed patients may report an 
increase in their interest in sex and levels of sexual activity (70). This is likely to be a 
function of the reversed vegetative features that are associated with atypical 
depression or alternatively it may represent a search for reassurance and intimacy. 
 
Impaired libido, difficulties initiating sexual activity, a decreased frequency of sexual 
intercourse, a loss of pleasure in or an aversion to intercourse and a reduction in the 
quality of sexual relationships have all been described. Difficulties with erection and 
ejaculation, dyspareunia and delayed or absent orgasm have also been associated with 
depression (70). 
Sexual pain disorders have not been specifically linked to major depression, but 
problems with desire, arousal and orgasmic function may all be associated (17). The 
resolution phase occurs passively following orgasm and problems with this phase 
have not been identified.  
 
1.3.3 Aetiology 
 
A detailed account of the mechanisms underlying the sexual dysfunction associated 
with depression is beyond the scope of this report. However, it is important that some 
attempt is made to correlate these factors with the neurobiology of normal sexual 
function that was discussed previously. 
 
Depression appears to have significant effects on hormonal function and it has been 
convincingly associated with hypothalamic-pituitary-gonadal (HPG) dysregulation. 
Psychological stress can affect the HPG axis and it has been shown to interfere with 
the activity of gonadotropin releasing hormone (75) and reduce testosterone levels in 
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primate models (76). In humans, psychological stress may either stimulate or suppress 
plasma testosterone levels (77). Testosterone has been found to be lower in depressed 
men (78) and to return to normal levels on recovery (79). Oestrogen has been found to 
be more effective than placebo in the treatment of pre-menopausal women with 
dysphoric symptoms (80) and severe antidepressant resistant depression (81), and 
oestradiol levels are lower in post-menopausal depressed women. Studies of 
luteinising hormone and follicle stimulating hormone secretion indicate a trend 
towards lower levels of these hormones in depressed pre-menopausal women and 
depressed men (82). Prolactin levels increase in response to stress in humans (83), 
possibly by direct inhibition of the gonadotropin releasing hormone stimulated release 
of luteinising hormone from the pituitary. The regulation of these sex hormones is 
clearly disordered during episodes of depression via central effects on the HPG axis. 
 
Glucocorticoids are thought to be important stress hormones. Their plasma levels 
increase in response to psychological stimuli dependent on personality and social 
factors, and high glucocorticoid levels suppress the HPG axis (84). Glucocorticoids 
can inhibit testicular testosterone production, an effect that may be caused directly by 
cortisol or indirectly by corticotropin releasing hormone or adrenocorticotropin (85). 
Major depression and hypercortisolaemia have consistently been associated with each 
other (86). This HPG axis hyperactivity is the basis of the cortisol non-suppression 
seen in dexamethasone suppression tests, the rate of which increases from mild (about 
30%) through too severe (about 70%) depression (70). The incidence of decreased 
libido is 1.5 to 2 times greater in dexamethasone suppression test non-suppressors 
compared to suppressors in major depression (87). Initial insomnia and decreased 
libido are the most significant contributors to variance in dexamethasone suppression 
test results (88). 
 
In the adrenal gland, cholesterol is metabolised to pregnenolone and then to 
dehydroepiandrosterone (DHEA) and its conjugated sulphate, dehydroepiandrosterone 
sulphate (DHEAS), or to progesterone and cortisol (70). DHEA and DHEAS are the 
most abundant products of the adrenal cortex in humans. Cortisol levels usually 
remain constant as one grows older, but DHEA and DHEAS levels rise during 
adolescence, peak in early adulthood and thereafter decline gradually. DHEA levels 
can change rapidly, in contrast to DHEAS levels that are stable and free of circadian 
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and menstrual changes. DHEA and DHEAS androgenic potency is 3% that of 
testosterone, but their blood levels in adult men are 100 to 150 times higher. They 
serve as a precursor to oestrogen, various androgens and androsterone. DHEA levels 
have been positively related with feelings of wellbeing in women, which in turn 
predicted measures of sexuality (89). The cortisol versus DHEA ratio is reduced in 
depression (90) and the ratio returns to normal upon recovery. DHEA is therefore a 
potential antidepressant. DHEA and DHEAS, pregnenolone and pregnenolone 
sulphate promote sexual behaviour in rats (91). Their increased concentrations in the 
amygdala and hypothalamus of male rats exposed to the scent of a receptive female 
suggests that they have a role in the perception or central nervous system integration 
of the scent. As sex steroid hormones, DHEA and DHEAS activity appears to involve 
more subtle interactions rather than the polarised and sexually overt behaviour and 
reactions characteristic of testosterone and oestrogen (92). 
 
The implication of these findings is that if depression is associated with altered levels 
of sex hormones, and if these hormonal changes are in turn correlated with negative 
effects on sexual function, then this is a likely explanation for the sexual dysfunction 
that is associated with depressive disorders. 
 
1.3.4 Management 
 
A detailed discussion of the management of sexual dysfunction associated with 
depression is beyond the scope of this report. However, management of the sexual 
symptoms is obviously aimed at treating the primary depressive condition according 
to accepted guidelines. 
 
The presence of sexual dysfunction clearly complicates the assessment and possibly 
management of a problem that is also a potential outcome of the very interventions 
used to treat depression. Although it makes sense to treat depressive disorders with an 
antidepressant with a low incidence of sexual dysfunction, particularly if sexual 
symptoms are a major part of the presenting illness there is little data to support this 
practice. 
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1.4 Sexual dysfunction and antidepressants 
 
Not only is sexual dysfunction a common symptom associated with depression, but 
the use of antidepressant medication can also cause sexual problems. The association 
of sexual dysfunction with the use of antidepressants has been conclusively 
demonstrated and antidepressants can clearly both aggravate and provoke sexual side 
effects (8, 55, 93). The added burden of AISD exacerbates an already difficult 
situation. As antidepressant treatment is usually a long-term undertaking, the presence 
of sexual dysfunction is likely to adversely affect the quality of life of patients, their 
partners and indirectly their families. Although there is not currently any reliable data 
on the subject, it is estimated that a significant proportion of patients who suffer from 
severe AISD will discontinue treatment because of that side effect (7). Sexual 
dysfunction is likely to have a significant impact on a patient’s compliance with 
medication and, therefore, their prognosis and the likelihood of relapse or recurrence. 
  
1.4.1 Epidemiology 
 
The exact prevalence of AISD is not clear. Early estimates that were based on 
spontaneous self-reporting substantially underestimated the frequency of the condition 
(94). Later estimates that specifically looked for this side effect reported rates from 
20% to 40% (93) and 10% and 50% (95). A prospective Spanish study in 2001 found 
that the overall incidence of sexual dysfunction in 1022 outpatients was 59.1% when 
all antidepressants were considered as a whole (7). A 2003 study of 4557 depressed 
patients in France reported that the frequency with which antidepressant drugs 
aggravated the sexual dysfunction associated with depression was even higher (71). It 
found that the frequency of sexual dysfunction was 71% amongst patients treated with 
antidepressants and 65% in untreated patients. Although estimates of the extent of the 
problem vary widely for various methodological reasons, the fact remains that AISD 
is a common problem. It is also true that more recent studies that have looked more 
aggressively for AISD have tended to report higher prevalence rates. Furthermore, 
there is some evidence that AISD has a greater prevalence in females (38.7%) 
compared to males (24.9%) (59). 
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Sexual dysfunction has been reported as a side effect of all antidepressants, but there 
is a certain amount of variation from one antidepressant to another in terms of the 
prevalence, clinical presentation and likely underlying mechanism that produce the 
AISD associated with their use. These differences are highlighted in the discussion 
that follows, but an emphasis is placed on those with serotonin re-uptake inhibition as 
their predominant mechanism of action. 
 
1.4.2 Clinical presentation and aetiology 
 
The specific types of sexual dysfunction associated with antidepressants include 
decreased libido, erectile dysfunction, delayed ejaculation or orgasm, anorgasmia and 
decreased genital sensation (96). The commonest complaints are those of decreased 
libido, impaired erection and difficulties with ejaculation or orgasm (70). Increased 
libido, improved or spontaneous erections or orgasms, priapism and altered sexual 
sensations and sensitivity have also been less commonly reported. There is also 
evidence to suggest that the direct effect of an antidepressant on diminishing libido 
and orgasm can have indirect adverse effects on sexual arousal over time (71). All 
sexual side effects, with the possible exception of rare cases of priapism, are thought 
to be reversible. It is important to note that not every sexual side effect is undesirable 
(8). For example, serotonergic antidepressants are often effective in the treatment of 
premature ejaculation and may also be beneficial in the control of paraphilias. 
 
Unfortunately, because both depression and its treatment can disturb the desire, 
arousal and orgasm phases of the human sexual response cycle, determining which of 
them is actually causing the sexual problems can be very difficult. Obviously, the 
temporal relationship between the onset of the sexual dysfunction and the onset of 
other depressive symptoms or antidepressant treatment may provide a clue. The 
precise nature of the sexual dysfunction may also suggest whether it is depression or 
its treatment that is the more likely cause. It has been reported that between 40% and 
50% of people with depression complain of diminished libido and problems with 
arousal in the month before diagnosis, while in comparison only 15% to 20% of 
patients experience difficulties with orgasm prior to taking an antidepressant (72). 
Complaints of orgasmic dysfunction with relatively little impairment in desire and 
arousal are therefore more likely to be caused by the antidepressant. However, it may 
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in many cases be impossible to discern the underlying cause, and in reality it is likely 
that multiple factors are involved. Figure 1.3 summarises the potential causes of 
sexual dysfunction that may be present during antidepressant treatment (12). 
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Figure 1.3 Potential causes of sexual dysfunction during antidepressant treatment 
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As a group, antidepressants can cause sedation, hormonal changes, disturbances of 
cholinergic-adrenergic balance, peripheral α-adrenergic antagonism, inhibition of 
nitric oxide and increased serotoninergic activity (17). All of these have been 
associated with the development of sexual dysfunction. However, the mechanisms 
that produce AISD are varied and generally poorly understood. A number of newer 
antidepressants with different mechanisms of action appear to be less likely to cause 
sexual dysfunction (71). These antidepressants with a lower incidence of sexual 
dysfunction are invariably either relatively free of serotonergic effects or have highly 
selective receptor activity at central serotoninergic synapses. 
 
1.4.2.1  Tricyclic antidepressants 
 
The approximate prevalence of sexual dysfunction with tricyclic antidepressants is 
about 30% (97). Specific problems include decreased libido, erectile dysfunction, 
delayed orgasm and impaired ejaculation. Painful ejaculation has been reported very 
rarely. These side effects can probably be best explained by the anticholinergic 
properties of tricyclic antidepressants, with the possible exception of decreased libido 
where their dopamine antagonist properties are likely to be involved (98). In addition, 
to a greater or lesser extent tricyclics also produce serotonin re-uptake inhibition and 
there appears to be some correlation between that and their propensity to cause sexual 
dysfunction. The prevalence of delayed orgasm with clomipramine may be double 
that of other tricyclics (97). Indeed, sexual dysfunction was reported in 95% of 
subjects involved in a trial of clomipramine for obsessive-compulsive disorder (99). 
This is possibly as a result of its strong serotonergic mechanism of action. The 
tricyclic antidepressants are a diverse group of compounds and their lack of receptor 
selectivity means that a combination of neurotransmitter systems are likely to be 
involved in the production of their sexual side effects. 
 
1.4.2.2  Monoamine oxidase inhibitors 
 
Overall, about 40% of patients taking irreversible monoamine oxidase inhibitors 
experience sexual dysfunction (7). Their specific side effects are similar to those of 
the tricyclic antidepressants (8). The inhibition of monoamine oxidase is neither a 
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neurotransmitter nor receptor selective mechanism of action, so the cause of sexual 
side effects with these agents is likely to involve numerous factors and all the 
monoamine neurotransmitters. The reversible monoamine oxidase inhibitor, 
moclobemide, appears to be much less likely to cause sexual dysfunction. The 
prevalence of sexual dysfunction with moclobemide has been reported as only 3.9% 
(7). 
 
1.4.2.3  Selective serotonin re-uptake inhibitors 
 
AISD is particularly common with serotonergic antidepressants (100). Overall, it 
appears that the prevalence of sexual difficulties in clients on serotonergic 
antidepressants is likely to be between 58% and 73% (7). Although this section refers 
to the SSRI antidepressants it is important to remember that venlafaxine and 
clomipramine also have a predominantly serotonergic mechanism of action. 
 
The specific sexual problems most strongly associated with SSRIs include decreased 
libido and delayed orgasm. In a major 2001 study of 1022 subjects citalopram and 
paroxetine emerged as the worst offenders. (7). Furthermore, significant differences in 
the prevalence of specific sexual side effects appeared to exist between the individual 
SSRIs. The overall incidence of sexual dysfunction for citalopram was 72.7%. The 
specific problems associated with its use included decreased libido (62.1%), delayed 
orgasm or ejaculation (63.6%), anorgasmia or no ejaculation (51.5%) and erectile 
dysfunction or decreased vaginal lubrication (34.8%). The overall incidence for 
paroxetine was 70.7%, while 63.9% experienced decreased libido and delayed orgasm 
or ejaculation, 52% anorgasmia or no ejaculation and 41.4% difficulties with erection 
or vaginal lubrication. For sertraline the overall incidence was 62.9%, with 54.7%, 
56.6%, 47.1% and 28.9% complaining of decreased libido, delayed orgasm or 
ejaculation, anorgasmia or no ejaculation and erectile dysfunction or decreased 
vaginal lubrication respectively. Fluvoxamine (62.3%, 48.1%, 54.5%, 37.6% and 
20.8%) and fluoxetine (57.7%, 50.2%, 49.5%, 39.1% and 21.8%) emerged from this 
study with the lowest incidence of sexual dysfunction. However, the overall incidence 
of sexual dysfunction with this class of antidepressants was found to be so high that 
individual differences are of limited clinical usefulness. Head-to-head comparative 
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studies are required as conclusions drawn from comparisons across trials are relatively 
meaningless. 
 
These results seem to suggest that paroxetine is associated with higher rates of erectile 
dysfunction and decreased vaginal lubrication, both of which represent a disturbance 
in the arousal phase of the sexual response cycle. This may be an exception to the rule 
or possibly due to selective reporting. Although delayed ejaculation and impaired 
arousal have been reported previously with fluoxetine (101), it is generally accepted 
that the SSRIs predominantly affect sexual desire and orgasm. Although they can and 
do impair arousal, this is a less common finding and it may in many cases be the 
indirect result of impairments in other phases of the sexual response cycle. Difficulties 
with orgasm have been particularly strongly associated with SSRIs, and have been 
present in approximately two-thirds of patients in a number of other studies (102, 
103). 
 
Complaints of decreased genital sensation are encountered in clinical settings, but this 
side effect has received little attention in the current literature. Penile anaesthesia has 
been reported with fluoxetine in rare cases (104), but this remains an unclear and 
controversial AISD. The role of serotonin in the peripheral nervous system may 
represent a plausible explanation of this side effect. 
 
The SSRIs are thought to cause decreased libido and their other sexual side effects by 
increasing synaptic concentrations of serotonin and stimulating 5HT2 and, possibly, 
5HT3 receptors (70). This results in decreased levels of dopamine activity in 
mesolimbic structures. SSRIs may cause delayed or absent ejaculation and orgasm by 
increasing serotonin release from neurones in the descending pathways between the 
brain and the dorsal horns of the spinal cord. Increased libido and spontaneous 
ejaculation or orgasm may be due to 5HT2A receptor antagonistic effects, although 
this is a more likely occurrence with the use of trazodone and nefazodone (95). 
Priapism, although it has been reported with SSRIs, is not considered to be primarily a 
serotonergic effect; it is likely to be caused by blocking the α-1 adrenoreceptor 
receptors that inhibit sympathetically mediated penile detumescence (105). 
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The impact of the SSRI antidepressants on sexual function is perhaps the most 
significant side effect of this class of drugs. It is certainly an important problem given 
their widespread and often long-term use. Unfortunately, the use of these agents is 
seldom accompanied by close monitoring for adverse events, particularly not for 
AISD. 
 
1.4.2.4  Other antidepressants 
 
The incidence of sexual dysfunction is high with venlafaxine, a serotonin and 
noradrenaline re-uptake inhibitor. It has been reported in 67.3% of patients using the 
agent (7). Specific problems associated with venlafaxine include decreased libido 
(60.0%), delayed orgasm or ejaculation (61.9%), anorgasmia or no ejaculation 
(41.8%) and erectile dysfunction or decreased vaginal lubrication (40.0%). Decreased 
libido and delayed orgasm are very common, but disturbances in other phases of the 
sexual response cycle are only somewhat less so. The mechanism involved is 
probably similar to that of the SSRIs at lower doses, although at higher doses other 
neurotransmitters are likely to contribute. This may explain the slightly different side 
effect profile which venlafaxine has in comparison with the SSRIs. 
 
The extent of sexual dysfunction associated with the use of trazodone has not been 
clarified (7). Impaired ejaculation and both increases and decreases in libido have 
been reported and trazodone has been used in some cases to promote erection. 
Priapism occurs in approximately 0.01% of subjects treated with trazodone (105). 
 
Mirtazapine appears to have relatively low rates of sexual dysfunction with an 
incidence reported as 24.4% (7). The most common sexual side efffects are decreased 
libido (20.4%) and delayed orgasm or ejaculation (18.4%). Anorgasmia or no 
ejaculation (8.2%) and erectile dysfunction or decreased vaginal lubrication (14.2%) 
are considerably less common. Mirtazapine’s selective antagonism of 5HT2 and 5HT3 
receptors is thought to be the main reason why it is associated with relatively little 
sexual dysfunction (106). 
 
The incidence of sexual dysfunction with nefazodone has been found to be as low as 
8.0% (3). Decreased libido (6.0%), delayed orgasm or ejaculation (2.0%), anorgasmia 
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or no ejaculation (2.0%) and erectile dysfunction or decreased vaginal lubrication 
(0.0%) are all extremely infrequent side effects. Nefazodone is a potent antagonist of 
5HT2 receptors and this is like to be the reason for its benign sexual side effect profile 
(107). 
 
The approximate prevalence of sexual dysfunction with reboxetine is estimated to be 
between 5% and 10% (108). Various abnormalities of orgasmic function have been 
described, but other phases of the sexual response cycle are thought to be relatively 
unaffected by this agent. Reboxetine is a noradrenaline re-uptake inhibitor with no 
serotonergic activity. 
 
The dopamine enhancing antidepressant, buproprion, appears to have a very low 
likelihood of causing sexual dysfunction although reliable estimates of the frequency 
of the problem are lacking (109). Buproprion does not enhance serotonergic activity at 
central synapses. 
 
In conclusion, major depression is a serious illness that is usually treated with an 
antidepressant medication. Depression can place a significant strain on relationships 
in its own right and the further burden of AISD, in addition to impinging on a major 
area of most peoples lives, is likely to adversely affect compliance and the likelihood 
of relapse. It negatively impacts on a patient’s quality of life, both directly and also 
through what are often already strained relationships with their partners. This is 
particularly significant given the often long-term nature of the illness and its 
treatment. More recent antidepressant drugs with different mechanisms of action 
appear to have less sexual dysfunction associated with their use. These agents have 
one of two things in common. Either their pharmacodynamic activity does not 
significantly involve serotonin, or, if the are serotonergic antidepressants, then they 
have selective 5HT2 (and possibly 5HT3) receptor antagonist properties. 
 
1.5 Management of antidepressant induced sexual dysfunction 
 
The management of AISD can be difficult and strategies for tackling the problem 
have historically been quite unsatisfactory. It is only with the advent of several newer 
antidepressants with less associated sexual dysfunction that viable treatment options 
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have become available. Nevertheless, there remain a significant number of patients for 
whom these agents are either unavailable or inappropriate, and highly serotonergic 
antidepressants are still commonly prescribed drugs for depressive disorders. AISD is 
significant problem, yet a paucity of clinical trial data makes it difficult to formulate 
an evidence-based approach to the management of these side effects. Any discussion 
of the management of AISD should begin with some guidelines for the assessment of 
the problem. Subsequently, a number of potential management strategies will be 
detailed and an attempt made to combine these into a rational approach to the 
management of the problem. 
 
1.5.1 Detection, screening and assessment 
 
An understanding of the human sexual response cycle and the DSM-IV classification 
of sexual dysfunction are an important pre-requisite to the assessment of sexual 
functioning. An assessment of sexual dysfunction should identify which phase or 
phases of the cycle are involved as well as whether the sexual symptoms meet DSM-
IV diagnostic criteria for a sexual disorder. Each disorder should be sub-typed as 
lifelong or acquired and as generalised or situational. It is obviously important to 
assess pre-morbid and life-long sexual function compared with the current 
presentation. However, a person’s subjective sense of sexual satisfaction is an 
important aspect of sexual functioning that is often overlooked and is not accounted 
for in the DSM-IV (17). Sexual satisfaction may be affected by diminished function in 
a specific phase of the sexual response cycle or by the global decrease in pleasure that 
is associated with depression and its treatment. Poor overall sexual satisfaction is a 
common complaint of people with AISD. 
  
The use of a screening tool or assessment instrument can be very useful. Such a tool 
should be brief, gender specific and identify which phase of the sexual response cycle 
is involved. It should also be as non-intrusive as possible, separate illness from the 
effects of medication and be able to monitor changes over time (17). There are 4 
existing scales that meet most of these criteria: the Arizona Sexual Experience Scale, 
the Changes in Sexual Functioning Questionnaire (Clinical Version), the Derogatis 
Interview for Sexual Functioning (Short Report) and the Rush Sexual Inventory. The 
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Feiger Sexual Function and Satisfaction Questionnaire is a useful instrument for 
describing orgasmic dysfunction and overall sexual satisfaction. 
 
As discussed earlier, patients tend not to spontaneously report sexual problems and 
often do not respond to casual questioning on the subject. This is no less true of AISD 
and the presence of sexual difficulties must be specifically inquired after. 
Interestingly, men appear more likely to report AISD (17). One strategy aimed at 
overcoming barriers to the discussion of sexual problems is to normalise the issue for 
the patient. This can be done by initially broaching the subject with a discussion of the 
frequency of sexual disorders in the general population or associated with specific 
treatments. Another is to simply provide basic psycho-education on the subject of 
sexual wellbeing and dysfunction. The discussion should follow a medical model and 
evaluate each phase of the cycle. Baseline measures of sexual functioning should be 
obtained whenever a diagnosis of major depressive disorder is made. In addition, it is 
important to note prior psychosexual adjustment and whether the current level of 
sexual functioning represents a change from baseline. An idea of fluctuations in 
sexual functioning associated with changes in the depressive illness and its treatment, 
or any alteration in psychosocial circumstances should be obtained over time. The use 
of a screening tool to identify problem areas requiring further discussion may also 
serve as an introduction to the topic. The discussions should refer generally to sexual 
activity rather than seeking details of specific behaviours in a way that a patient might 
view as intrusive. 
 
A thorough assessment of AISD should include the six elements summarised in Table 
1.2 (17). This involves a search for other potential causes of the sexual dysfunction as 
well as an appraisal of each phase of the sexual response cycle and the person’s 
current level of sexual satisfaction. The assessment of sexual dysfunction in 
depression can be complicated by difficulties in determining the relative contribution 
of depression itself, of medication, and of underlying pre-existing sexual dysfunction 
(110). However, a thorough understanding of the problem is essential as it determines 
what is likely to be the best management strategy. It is also important that ongoing 
monitoring for improvement occurs over time. 
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Table 1.2 Assessment of antidepressant induced sexual dysfunction 
 
1. Take a thorough sexual history: 
• Onset of puberty 
• Age and nature of the person’s first sexual experience 
• Childhood sexual abuse or adult sexual trauma 
• Reproductive function and pregnancy 
• Current phase of menstrual cycle 
• Peri-menopausal symptoms and menopausal transition 
• Current relationship status and opportunity for sexual activity  
 
2. Take a psychiatric and medical history: 
• Look for past and present conditions and document diagnoses 
• Screen for psychiatric illnesses commonly associated with sexual 
dysfunction (eg. mood and anxiety disorders) 
• Screen for common medical causes of sexual dysfunction (eg. 
neurological, endocrine, auto-immune and urogenital disorders) 
• Ask specifically about infectious and sexually transmitted diseases 
 
3. Identify all substances that might contribute to sexual dysfunction: 
• Psychiatric medications 
• Medications for general medical conditions 
• Prescription and over the counter preparations 
• Alcohol, nicotine and illicit drugs 
 
4. Evaluate the current level of sexual functioning: 
• Pre-morbid and pre-treatment level of sexual functioning 
• Onset and nature of the sexual dysfunction 
• Specific and relative effects on each phase of the sexual response cycle 
(whether desire, arousal or orgasm are primarily effected) 
• Severity of symptoms, subjective distress and overall sexual satisfaction 
• Use a screening instrument or rating scale  
• Impact on partner or others 
 
5. Perform a physical examination: 
• Brief general examination to screen for physical signs 
• Targeted examination of particular systems as informed by the history 
• Full neurological or urogenital examination if appropriate 
 
6. Order special investigations as indicated clinically: 
• Exclude or evaluate underlying psychiatric and medical conditions 
• Endocrine investigations (sex hormone binding globulin, free and total 
testosterone, prolactin levels, oestradiol, follicle stimulating hormone and 
luteinizing hormone levels, thyroid function tests) 
• Other common laboratory measures to screen for (blood glucose, 
haemoglobin A1C and lipid levels) 
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1.5.2 Management strategies 
 
Once a problem with sexual function has been identified and determined to be 
secondary to the effects of an antidepressant there are a number of possible strategies 
for managing the condition. It is convenient to divide these strategies into three broad 
categories: conservative or non-pharmacological approaches, changing the 
antidepressant medication and adjunctive strategies. Any decision about which option 
to choose, and the decision about whether to do anything at all, should be made in 
close co-operation with the patient. 
 
1.5.2.1  Conservative, non-pharmacological approaches 
 
In cases when the duration of antidepressant therapy is not expected to be long and the 
patient is agreeable it may be appropriate to do nothing. Furthermore, a small 
proportion of patients will elect to live with the sexual problems caused by their 
antidepressant therapy either because their sexual functioning is better overall than 
when they were depressed or because of a lack of interest or opportunity for sexual 
activity. Factors like age, relationship status, personality and a variety of psychosocial 
factors may also effect the patient’s decision. In such cases the decision should be 
respected. The role of the clinician is to identify and monitor the problem and provide 
psycho-education regarding treatment options. It should however never be assumed 
that a person does not need nor want to function better sexually. 
 
The most common approach is to wait and see whether tolerance develops to the side 
effects. It has been reported that in 42% of cases of AISD the approach used is to 
await spontaneous remission (71). There is evidence to suggest that this will be an 
acceptable strategy for a small proportion of patients (111). It has been reported that 
the spontaneous remission of AISD occurs in approximately 10% of cases and that a 
further 11% will experience a partial remission (7). However, the majority of patients 
will find this an unsatisfactory option, particularly if antidepressant therapy is likely to 
be ongoing. Although it is reasonable to wait and see for a period of time and to 
monitor for any spontaneous improvement, this approach is often incorrectly used as a 
way to avoid addressing the problem. 
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A number of other minimally disruptive strategies have been used to manage AISD. It 
may be useful try and time the patient’s ingestion of medication so that it does not 
correspond with sexual activity. The term delayed dosing has been used to describe 
this practice and usually the person will only take their daily dose of antidepressant 
medication after they have engaged in sexual activity (112). Drug holidays or 
stopping the medication for short periods particularly when sexual activity is 
anticipated, may also be useful (113). These two strategies are obviously more likely 
to be useful with the shorter acting antidepressants, but unfortunately they also carry 
with them a risk of discontinuation symptoms. Drug holidays are seldom used (71). 
Dosage reduction can some times be helpful (114). Unfortunately, all three of these 
strategies are associated with the risk of relapse or recurrence and patients should be 
warned that depressive or anxiety symptoms could re-emerge. The patient, family and 
clinician should monitor the mental state carefully when employing these strategies. 
 
Psychotherapeutic interventions may be a further option. Although the main cause of 
the sexual problem is the antidepressant, it is worth remembering that sexual activity 
does not take place in a vacuum and that psychosocial factors are almost certainly at 
play. It may well be useful to employ behavioural and cognitive behavioural 
techniques, relationship counselling and perhaps a range of other psychotherapies that 
are the cornerstone of sex therapy. Unfortunately, little is known about the efficacy of 
these approaches in AISD and further investigation is needed in this area (115). 
Nevertheless, basic psychosocial interventions should be a part of any management 
plan and not be left as a last resort, particularly when the risks of changes to 
medication are high. 
 
1.5.2.2  Changing the antidepressant 
 
Because less invasive strategies may in fact end up being more disruptive than 
invasive strategies, it is therefore often more logical to switch to a different 
antidepressant. Generally one would choose an alternative antidepressant that is less 
associated with the specific sexual difficulty being experienced. Switching to a non-
serotonergic antidepressant or to another serotonergic antidepressant that is less 
associated with sexual problems may be an appropriate strategy for some patients 
(116). Examples of suggested antidepressants are bupropion, nefazodone, mirtazapine 
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(112) and reboxetine (117). The sexual side effect profiles of these agents have been 
described previously. The potential side effects of these drugs should be matched to 
the patient’s clinical condition, physical condition, sensitivity to side effects and 
experience of sexual dysfunction.  
 
Guidelines produced by the American Psychiatric Association recommend the 
substitution of antidepressants causing sexual dysfunction with one of these newer 
drugs in cases where patients complain of sex problems (118). In about 39% of cases 
physicians manage AISD by changing antidepressant treatment (71). 
 
The drawback of this strategy is that any change of medication is accompanied by risk 
of relapse or recurrence. The fact that a patient recovered from their depressive or 
anxiety disorder on one agent is no guarantee that another agent will be as efficacious. 
There is also no guarantee that the patient will be free of sexual difficulties on the new 
medication, or that they will not experience some other equally or more distressing 
side effect. Furthermore, a change to a different antidepressant will simply not be an 
option for a significant proportion of patients. This may be due to the severity of their 
past episodes and the risks associated with relapse, a previous history of poor 
response or intolerable side effects on those agents, or such mundane factors as cost 
and availability.  
 
1.5.2.3  Adjunctive strategies 
 
Because the above options are of limited usefulness and at best are only viable for a 
modest percentage of patients suffering from AISD, adjunctive strategies have been 
enthusiastically pursued. The term adjunctive refers to the use of a second or add-on 
agent to augment the pharmacological action of the antidepressant. In the case of 
AISD it is hoped that use of an augmenting agent will modify the side effect profile of 
the first drug. Unfortunately, adjunctive therapies are rarely proposed to patients (71) 
and there is a limited amount of clinical trial evidence on their use for this problem 
(112). Controlled data is lacking and is mostly in the form of case reports and small 
open label studies. As a result these adjunctive strategies are based mainly on a 
combination of current understanding of the mechanism of antidepressant action and 
the neurobiology of the sexual response phenomenon. The decision is often based 
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more on the anecdotal experience of the treating clinician than any solid evidence 
base. The use of a number of agents for the pharmacological treatment of AISD has 
been suggested. They have usually been used anecdotally as augmenting agents to 
target sexual side effects in cases where patients continue to take their antidepressant 
therapy. 
 
Dopamine clearly plays an important role in the neurochemistry of the sexual 
response cycle and several open studies and case reports have suggested the 
usefulness of agents augmenting dopaminergic neurotransmission as adjunctive 
therapies. Bupropion, taken either daily (119, 120) or on an as needed basis (121) may 
be beneficial, particularly for disturbances of orgasm. Doses of between 75 and 150 
milligrams (mg) per day in divided doses are recommended for patients on SSRIs or 
venlafaxine (12). The usual precautions for bupropion should be taken and possible 
drug interactions considered. Amantadine, a dopaminergic agonist, has been reported 
to be useful, again for orgasmic dysfunction (122, 123). A dose of 100 mg twice daily 
has been recommended, but caution is advised in those patients predisposed to 
psychosis (12). The usefulness of ropinirole has also been suggested (124). 
 
A variety of stimulants including pemoline (18.75 to 75 mg per day), 
dextroamphetamine (5 to 40 mg per day) and methyphenidate (5 to 40 mg per day) 
have been reported to be of value (125, 126). However, their use as augmentation 
strategies is not without its own risks, most notably agitation, insomnia and misuse. 
Positive effects have been demonstrated on desire, arousal and orgasm in those 
patients taking SSRIs and venlafaxine. 
 
The cholinergic enhancers bethanechol (10 to 50 mg per day) and neostigmine (50 mg 
taken one hour before sex or up to 200mg per day in divided doses) have been used 
with some success for arousal difficulties on antidepressants with anti-cholinergic side 
effects (12). 
 
Noradrenaline is involved in the sexual response cycle and noradrenergic agents have 
also been investigated. Yohimbine, a α-2 adrenergic receptor antagonist, was reported 
to be of use for all phases of the sexual response cycle (127, 104, 128). A dose of  
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5.4 mg has been suggested, but caution is advised as the agent can exacerbate anxiety 
and precipitate panic attacks (12). 
 
An open trial of sildenafil reported efficacy in AISD (129). The efficacy of sildenafil 
for the treatment of AISD has been confirmed in a 6-week, randomised, placebo-
controlled trial of 90 men (138) and also for the treatment of ejaculatory delay caused 
by selective serotonin re-uptake inhibitors or SSRIs (139). A dose of 50 to 100 mg per 
day is suggested for difficulties with desire, arousal and orgasm (12). The agent is 
contra-indicated for use with nitrates and the usual precautions should be followed 
when prescribing sildenafil. 
 
However, it is agents that modify serotoninergic neurotransmission that have the 
greatest face validity in the treatment of SSRI induced sexual dysfunction. This is not 
surprising considering the modulatory influence of serotonin in the sexual response 
cycle and the proposed mechanisms by which serotonergic antidepressants are 
thought to cause AISD. Cyproheptadine, a 5HT2 and histamine antagonist, is perhaps 
the most widely used agent for this indication, though evidence for its benefits on 
orgasm are those best documented (130, 131, 132, 133, 134, 135, 136). The 
recommended dosage range is 4 to 12 mg as required (12). Cyproheptadine useful for 
the AISD associated with both SSRIs and venlafaxine, but it can be sedating and has 
been associated with the re-emergence of depressive symptoms. Agents which 
antagonise 5HT2 receptors, such as nefazodone (50 to 150 mg per day), have been 
shown to be useful as augmentation agents (137). This is in addition to the fact that 
they appear to be associated with lower levels of sexual dysfunction than SSRI’s, 
when used alone in the treatment of depression. Mirtazapine (15 to 45 mg per day), an 
antagonist of 5HT2, 5HT3 and α1 and α2 adrenergic receptors, similarly, is associated 
with lower levels of antidepressant induced sexual dysfunction and may be useful as 
an augmentation strategy. Both nefazodone and mirtazapine appear to be most useful 
for orgasmic disturbance (12). The potential risks of using multiple antidepressants in 
combination should not be overlooked when choosing this option. 
 
Ginkgo biloba has been reported as useful for difficulties with libido, arousal and 
orgasm at doses between 180 and 240 mg per per day in divided doses (12). However, 
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negative studies do exist for the treatment of AISD with both Ginkgo biloba (140) and 
sumatriptan (141).  
 
In a single case report granisetron, an anti-emetic with 5HT3 antagonism as its 
mechanism of action, has been reported as useful in this indication (142). A previous 
positive open label study (141) has suggested that granisetron may be a promising 
agent meriting study under double blind conditions. The recommended dose is 1 mg 
per day as required. Two small negative studies have, however, failed to establish the 
usefulness of granisetron (143, 144). 
 
In conclusion, and notwithstanding the lack of good evidence-based data, Figure 1.4 
outlines a rational approach to the treatment of AISD. The flow diagram represents 
the author’s opinion and clinical experience. It reflects a balance between the existing 
level of evidence for particular interventions and that intervention’s relative 
tolerability. It is impossible in such a broad guideline to take into account the myriad 
of individual factors that might impact on the decision as to which intervention is 
most appropriate for a particular patient. In all instances the use of these strategies 
should be preceded by a thorough assessment and be individually tailored to the 
patient’s specific needs. A patient’s response or failure to respond to an intervention 
should be actively followed-up by ongoing monitoring. 
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ppp The primary 
psychiatric disorder is 
stable and well 
controlled on an 
antidepressant, but 
significant AISD is 
present. 
The primary 
psychiatric disorder is 
poorly or partially 
controlled on an 
antidepressant, and 
significant AISD is 
present. 
The primary 
psychiatric condition is 
active and untreated 
(sexual dysfunction 
may or may not be 
present). 
If an antidepressant is 
indicated choose one 
that is associated with 
low rates of AISD: 
• Mirtazapine 
• Nefazodone 
• Reboxetine 
• Moclobemide 
• Bupropion 
Change to an 
antidepressant that is 
associated with low 
rates of AISD: 
• Mirtazapine 
• Nefazodone 
• Reboxetine 
• Moclobemide 
• Buproprion 
Conservative, non-
pharmacolgical 
measures: 
• Await tolerance 
• Reduce dose 
• Delayed dosing 
• Psychotherapeutic 
interventions 
1st line augmentation: 
• Bupropion 
• Buspirone 
• Mirtazepine 
• Nefazodone 
2nd line augmentation: 
• Amantadine 
• Cholinergic agents 
• Cyproheptadine 
• Ginko biloba 
• Granisetron 
• Sildenafil 
• Stimulants 
• Yohimbine 
Last line strategies: 
• Drug holidays 
• Combinations of  
• Novel or innovative 
approaches 
Figure 1.4 Treatment of antidepressant induced sexual dysfunction 
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1.6 Granisetron 
 
Granisetron is classified as an anti-emetic and anti-vertigo medication (145). It is 
available in a 3 mg ampoule for intravenous injection, and in an oral 1 mg tablet. The 
latter will be the preparation used for this trial. The recommended anti-emetic dose is 
1 mg twice daily orally. Granisetron is a selective antagonist of 5HT3 receptors and 
has minimal affinity for other serotonin binding sites. It is thought to produce its anti-
emetic effect by antagonising 5HT3 receptors on abdominal vagal afferents that are 
stimulated by serotonin released from the gastro-intestinal mucosa when cytostatic 
agents are administered (146). It also acts on 5HT3 receptors in the central nervous 
system, but this does not appear to contribute significantly to the anti-emetic effect. 
 
Granisetron is considered to be a safe agent. It has been thoroughly evaluated in large 
volunteer studies (147). Both single and repeated intravenous doses greatly in excess 
of that which is recommended were well tolerated by healthy volunteers. No serious 
adverse events were reported. There were no consistent or clinically important 
cardiovascular effects. Granisetron did not influence the volunteers’ mental state, 
psychomotor performance or electroencephalogram. With repeated administration of 
doses far in excess of that which would be used clinically, two volunteers developed a 
transient and self-limiting elevation of alanine transaminase and aspartate 
transaminase, which may have been produced by granisetron. There was no other 
evidence of a drug-related effect on clinical chemistry or haematology. The only 
adverse event that was reported consistently more frequently with granisetron than 
placebo was constipation. Generally this subsided spontaneously after 24 to 72 hours, 
and in no case did it necessitate withdrawal from the study or the use of a laxative. 
Headaches and somnolence have been reported. Minor skin reactions are infrequent. 
In overdose the predominant symptom is headache. There is no antidote, and 
management is supportive. 
 
Granisetron exhibits linear kinetics, and is rapidly eliminated (148). It is metabolised 
in the liver and excreted in the urine and faeces. Present experience indicates that no 
dosage adjustment is necessary, but usual care should be taken when prescribing it to 
the elderly or those with hepatic or renal impairment. There is no drug interaction 
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with benzodiazepines, antipsychotics and anti-ulcer drugs. It does interact with 
phenobarbitone. 
 
Granisetron’s highly selective antagonism of 5HT3 receptors in the central nervous 
system makes it a useful agent with which to block increased serotonergic activity at 
this receptor. 
 
1.7 Hypothesis and overall aims 
 
The possibility that agents which antagonise 5HT3 receptors might counteract the 
enhanced neurotransmission at that receptor caused by serotonergic antidepressants 
and thus reduce the sexual side effects of those agents prompted this trial of 
granisetron. The aim of the study was to assess the efficacy of granisetron as an 
augmentation strategy for the treatment of AISD in women taking a range of 
serotonergic antidepressants. Its purpose was to test the hypothesis that granisetron 
would be more efficacious than placebo for this indication in a randomised controlled 
trial.  
 
A number of factors contributed toward the development and undertaking of this 
study. 
 
Firstly, scientific value and benefit. There was considerable interest at that time in the 
5HT3 receptor as a possible mechanism by which serotonergic antidepressants 
produced their sexual side effects. Furthermore, the relative roles of the 5HT3 and 
5HT2 receptor in AISD were not as clear as they are now. Whether the outcome of 
this study demonstrated a significant improvement in sexual dysfunction for 
granisetron over placebo or not, it was hoped that the mechanism by which 
serotonergic antidepressants caused sexual dysfunction might be better understood. 
 
Secondly, as discussed previously, current management options for AISD are 
inadequate and those adjunctive treatment strategies that do exist are not supported by 
randomised controlled trials. It was thought that a viable and validated augmentation 
strategy for the treatment of AISD would greatly improve the tools at the clinician’s 
disposal and the quality of life of patients with this problem. Switching strategies 
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carry an appreciable risk of relapse. The newer antidepressants like nefazodone and 
mirtazapine are associated with lower, but not altogether insignificant, levels of sexual 
side effects, and it is often not possible to treat all individuals with these agents. 
Adjunctive therapies were therefore considered to be of benefit to patients.  
 
Thirdly, it is widely accepted that sexual problems in general and AISD in particular 
are largely under-reported. It was hoped that the study would highlight the extent of 
the problem and the necessity for careful screening and treatment. 
 
Furthermore, it appears that there is a significant psychological component to even 
AISD. This is evidenced by the extent to which a placebo response is observed in 
trials of this nature. It was therefore anticipated that participants in the trial would not 
only be safe from harm, but that they would also experience an improvement in their 
sexual functioning whether they received the active drug or not. There is certainly 
evidence to suggest that patients often benefit from the close scrutiny their symptoms 
receive during the course of a clinical trial. 
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2.0 MATERIALS AND METHODS 
 
2.1 Overview of the research design 
 
The design of this prospective study was that of a randomised double blind, placebo 
controlled drug trial. Following an initial screening assessment to determine whether 
they were suitable for the study participants were randomly and consecutively 
assigned to one or other of the two trial groups. Both the investigator and the 
participants were blinded as to which group they had been assigned and which 
medication was being administered. The blind was maintained for the duration of the 
study and was only broken at its conclusion for the purpose of statistical analysis.  
 
The treatment group received the active drug and the placebo group an inactive 
placebo preparation. The participants were followed up for a 2-week study period 
during which time their clinical condition was monitored and changes in their 
symptoms were objectively measured using three rating scales. An assessment was to 
be attempted on the day of study termination if the patient withdrew prior to the end 
of the trial. 
 
2.2 Study group 
 
A total of 12 females aged between 18 and 65 participated in the study. They were 
recruited from the outpatient psychiatry department at Tara, The H. Moross Centre as 
well as from three private psychiatric practices in South Africa. In an attempt to keep 
the sample as homogenous as possible and to avoid the use of different rating scales 
for male sexual dysfunction, entry to the study was restricted to only females. A 
clinical diagnosis was made according DSM-IV criteria and a structured clinical 
interview, the Mini-International Neuropsychiatric Interview (MINI), was done at 
baseline to confirm the diagnosis. 
 
2.2.1 Inclusion criteria 
 
In order to be included in the study participants had to be experiencing AISD. No 
specific diagnosis was required for inclusion in the trial, but it was anticipated that the 
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majority of subjects would be diagnosed with major depressive disorder or one of the 
anxiety disorders. The presenting symptoms of their psychiatric illness had to be in 
remission as defined by a Clinical Global Impression (CGI) Severity of Illness sub-
scale score of 1 or 2. All participants had to be taking antidepressant maintenance 
treatment for their psychiatric illness. The range of acceptable antidepressants 
included any which had serotonergic activity as their predominant mechanism of 
action. Every woman participating in the trial was required to be using contraception 
(an oral contraceptive, an implant, an intra-uterine device or the double barrier 
method) unless she was post-menopausal. 
 
2.2.2 Exclusion criteria 
 
Any participants who had undergone a change in their psychotropic treatment in the 
last two months were excluded from the study, as were all those with an active, 
clinically significant Axis I disorder as defined as a CGI Severity of Illness sub-scale 
score greater than 2. If a comorbid Axis 1 disorder was present it also had to be 
judged to be in remission. Also excluded were participants who displayed an acute 
systemic medical disorder or a medical disorder that required frequent changes in 
medication. Patients with pre-existing cardiac disease were also excluded.  Any 
participants that were unable to comply with either the requirements of informed 
consent or the treatment protocol were excluded. Patients with a history of sexual 
dysfunction prior to either the primary illness or treatment were excluded. 
 
2.3 Instruments and measurements 
 
2.3.1 Mini-International Neuropsychiatric Interview 
 
The MINI is a widely used research tool. It was designed as a brief structured 
interview for the major Axis I disorders in DSM-IV and the International 
Classification of Diseases and Related Health Problems, 10th edition (ICD-10). 
Evaluation of the MINI has shown that the tool has acceptably high validation and 
reliability scores (149). The Clinician Rated (Version 4.4) edition was used for the 
purposes of this study. The MINI comprises seventeen broad categories of questions 
that cover a range of psychiatric disorders. It not only makes psychiatric diagnoses 
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according to DSM-IV criteria, but also provides information on whether these 
episodes are current or past. 
 
2.3.2 Clinical Global Impression Scale 
 
The CGI is a crude but well-validated tool for assessing the overall severity of 
psychiatric illness (150). It has been extensively used in numerous clinical and 
research settings. There are 2 sub-scales to the CGI, both of which were used in this 
study. 
 
The Severity of Illness sub-scale of the CGI rates the investigator’s assessment of the 
overall severity of the participant’s clinical condition at the time of that interview. It 
provides no longitudinal information. It is also important to note that this assessment 
referred to the overall severity of the psychiatric condition and not to the severity of 
sexual dysfunction. The investigator simply scores the participant as the most 
appropriate of the scale’s seven items ranging from “1. Normal, not at all mentally ill” 
to “7. Among the most severely mentally ill”. In this study the severity sub-scale was 
administered at baseline and all subsequent visits. It was used to exclude participants 
from the study who had an active clinically significant Axis 1 psychiatric disorder. 
This was quantified as a CGI severity score of greater than 2. Furthermore, should this 
score have risen to greater than 2 on any of the subsequent visits then the participant 
would have been excluded from the study. 
 
The Global Improvement sub-scale of the CGI rates the investigator’s assessment of 
any change in the participants clinical condition compared to the last CGI assessment. 
It was therefore completed at Visit 2 and Visit 3, but not at baseline (when no 
previous rating existed). It provides information about change over time. It is again 
important to note that the CGI global improvement score referred to any change in the 
participants overall clinical condition and not to their sexual dysfunction, although in 
reality it could be anticipated that a reduction in sexual dysfunction was likely to 
result in a global improvement. The investigator scores the participant’s global 
improvement on a 7 item scale ranging from “1. Very much improved” to “7. Very 
much worse”. Should a participant have had a CGI global improvement score of 6 or 
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more (much worse or very much worse) then they would have been withdrawn from 
the study. 
 
A copy of the CGI Scale as it was used in this study is provided in Appendix C. 
 
2.3.3 Arizona Sexual Experience Scale 
 
The Arizona Sexual Experience Scale has been validated and widely used in clinical 
drug trials (151). It includes 6 items, although only 5 of them are relevant to females. 
The item related to erectile dysfunction was not used in this study which included 
only female participants. The scale rates a number of aspects of sexual functioning 
including interest in sex, arousal, orgasm and sexual satisfaction, as well as 
improvement since the last medication change. It may be used for heterosexual and 
homosexual populations regardless of the availability of a sexual partner. A global 
score greater than or equal to 19 or any individual question responses of 5 or more 
indicate significant sexual dysfunction. The scale may be used to monitor changes in 
function over time. The investigator administers the scale and the participant’s 
responses are recorded on a 6 point Likeart type scale. 
 
The scale was administered at baseline, day 7 and day 14 of the trial period. It was 
one of the two primary measures of sexual dysfunction used in the study. It was used 
in addition to the Feiger Sexual Function and Satisfaction Questionnaire because it 
covers a range of parameters of sexual function, whereas the Feiger scale focuses 
mainly on orgasm. A copy of the Arizona Sexual Experience Scale has been included 
in Appendix D. 
 
2.3.4 Feiger Sexual Function and Satisfaction Questionnaire 
 
The Feiger Sexual Function and Satisfaction Questionnaire has also been validated 
and wide used (152). It also comprises 6 items that include enjoyment and overall 
satisfaction, but focus predominantly on the participant’s experience of and ability to 
achieve orgasm. The investigator administers the scale and the participant’s responses 
are recorded on a 4 or 5 point Likeart type scale.  
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The scale was administered at baseline, day 7 and day 14 of the trial period. It was 
one of the 2 primary measures of sexual dysfunction used in the study. A copy of the 
Feiger Sexual Function and Satisfaction Questionnaire is included in Appendix E. 
 
2.4 The study procedure 
 
The study procedure is outlined in the schedule of visits included in Figure 2.1; it is 
slightly modified from the one that was included in each participant’s clinical research 
file. 
 
2.4.1 Screening assessment 
 
Each potential participant referred to the investigator underwent an initial screening 
visit to determine whether they were suitable to participate in the trial. If they did 
appear suitable they received extensive education regarding the study and their right 
not to be involved. If they were willing to participate they then signed the Information 
and Consent Form to give their written informed consent. They were provided with a 
copy of the Information and Consent Form, which is also included in Appendix C. 
Once they had signed the consent form some patients progressed immediately to the 
baseline assessment while others did the baseline assessment on a separate occasion. 
 
2.4.2 Visit 1 
 
The baseline assessment included a semi-structured interview designed by the 
investigator to gather relevant demographic and clinical data. A copy of this semi-
structured interview, the Initial Assessment Form, is included in Appendix D. The 
MINI, CGI Severity of Illness sub-scale, the Arizona Sexual Experience Scale and the 
Feiger Sexual Function and Satisfaction Questionnaire were all completed at this vist. 
The participants were then randomised to receive either granisetron one tablet (1 mg) 
or placebo at night. 
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ITEMS TO BE COMPLETED 
 
VISIT 1 
BASELINE 
DAY 0 
 
 
VISIT 2 
WEEK 1 
DAY 7 
 
VISIT 3 
WEEK 2 
DAY 14 
Information and Consent Form 
 
 
 
 
   
Initial Assessment Form 
 
 
 
 
   
Mini-International Neuro-psychiatric 
Interview (MINI) 
 
 
 
   
Clinical Global Impression Scale 
(Severity of Illness) 
 
 
 
   
Clinical Global Impression Scale 
(Global Improvement) 
 
 
 
   
Arizona Sexual Experience Scale 
 
 
 
 
   
Feiger Sexual Function and Satisfaction 
Questionnaire 
 
 
 
   
Notes: 
• Clinical condition 
• Adverse events 
• Medication changes 
   
 
 
Figure 2.1 Schedule of visits as included in each clinical research file (grey areas 
indicate that the item is to be completed at that visit) 
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2.4.3 Visits 2 and 3 
 
All participants underwent a brief unstructured interview to ascertain whether there 
had been any changes in their clinical condition. They were asked about their 
compliance with trial medication and if they had taken any additional treatments or 
changed their psychiatric medication in any way. Information that the patient 
volunteered regarding their sexual dysfunction was recorded. Subjects were also 
asked about any side effects or adverse events that they had experienced. This 
information was recorded in their research file and a brief note of any relevant 
information was also made in their clinical file.The participants were then rated on 
both the CGI severity and global improvement sub-scales. The Arizona Sexual 
Experience Scale and the Feiger Sexual Function and Satisfaction Questionnaire were 
also completed. 
 
2.5 Statistical analysis 
 
The analysis was performed on data collected from 12 participants, 5 of them in the 
granisetron group and 7 in the placebo group. In addition to the CGI scores and the 
two rating scales used to assess sexual dysfunction, the analysis also included 
descriptive statistics of demographic and clinical data reported as means and standard 
deviations. 
 
Statistical analysis was performed as placebo versus granisetron. The Kruskal-Wallis 
Test for non-parametric analysis of variance was used to assess differences in 
proportion of the means between the two groups. Both total and individual item scores 
from the rating scales were compared. Absolute changes on the rating scales were 
calculated by comparing the score at baseline with that at termination. All tests were 
two-tailed and p values of less than 0.05 were considered to be statistically significant. 
The power of the analysis was weakened as a result of the low number of participants. 
 
Subjects that had been randomised into the study and subsequently withdrew consent 
or discontinued participating were included in the statistical analysis. Provided they 
had undergone the first assessment and had baseline data recorded that last 
observation was carried forward. 
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2.6  Ethical aspects 
 
Whenever trial medication is administered to human subjects a question arises as to 
whether any possible risks to the patient are sufficiently counterbalanced by the 
anticipated benefits to the patient, the broader community or scientific knowledge. 
Particularly in clinical drug trials, the safety of the patient is paramount. In the case of 
this study risk were low. Granisetron is considered a safe and well-tolerated agent 
with no known serious side effects (147). It is not a new or experimental drug. The 
anticipated benefits for the participants and the scientific reasons for doing the study 
have already been discussed at some length.  
 
All participants received extensive education and gave full written informed consent 
before they were entered into the study. Those who were unwilling or unable to give 
their written informed consent were excluded from participation. The Committee for 
Research on Human Subjects of the University of the Witwatersrand approved the 
study protocol. In addition, permission was obtained from Tara, The H. Moross 
Centre to conduct the study in its outpatient department. 
 
To protect confidentiality all study material was marked only with the participant’s 
initials and study number. All data was completely de-identified before being entered 
into an electronic database and only the investigator held a record that could identify 
the responses of individual participants based on their initials. Their clinical file was 
marked with a sticker to ensure that any clinician seeing the patient was aware that 
they were participating in a clinical trial. 
 
Participants were immediately withdrawn from the study if they withdrew their 
consent, deteriorated or experience distressing adverse effects to the trial medication. 
The study was conducted in accordance with the Medical Research Council guidelines 
for medical research. 
 
2.7 Financial aspects 
 
This study was an investigator-initiated research project. The investigator and the 
Department of Psychiatry at the University of the Witwatersrand were responsible for 
 59
the minimal expenses related to conducting the study. GlaxoSmithKline supplied 
granisetron samples to the investigator at no cost. They did not, however, sponsor any 
other aspect of the trial.  
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3.0 RESULTS 
 
3.1 Recruitment and randomisation 
 
During the recruitment phase of the study approximately 40 women were screened for 
their suitability and approached for their informed consent to participate. Ultimately, 
only 12 of them were randomised into the trial. Of those 12 women, 5 were 
randomised to the granisetron group and 7 to the placebo group. There were 2 
premature discontinuations, both of which were from the granisetron group. Both the 
subjects discontinued after they had been randomised but before they had commenced 
taking any trial medication. The reason given for discontinuation was related to a 
change in their personal circumstances rather than to the study itself. 
 
3.2 Demographic and clinical variables 
 
All participants were female in accordance with the study protocol that excluded 
males from the sample. The mean age ± SD of the granisetron group was 43.25 ± 
16.82 and that of the placebo group was 33.00 ± 5.29 years. All participants were 
either married or involved in a long-term relationship at the time that they participated 
in the trial. Three participants were married in the granisetron group and 5 were 
married in the placebo group. In the granisetron group 4 participants and in the 
placebo group 5 participants described themselves as being formally employed. The 
two groups did not differ significantly at baseline on any of the demographic 
parameters.  
 
All 12 participants had an Axis I diagnosis of major depressive disorder in remission. 
In the granisetron group there were no other past or present Axis I disorders 
diagnosed. In the granisetron group, 3 of the participants had a single comorbid DSM-
IV disorder which was in remission on Axis I (generalised anxiety disorder, panic 
disorder or bulimia nervosa). One participant in the granisetron group and 1 
participant in the placebo group were diagnosed with Cluster C personality traits. In 
all the other participants Axis II disorders were deferred. In terms of comorbid 
medical conditions, 1 participant in the granisetron group had multiple stable medical 
conditions (hypercholesterolaemia, hypertension and backache) and 1 participant had 
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a single stable medical condition (menopause) reflected on Axis III. In the placebo 
group 2 participants had a single Axis III diagnosis (hypotension and possible 
temporal lobe epilepsy). No significant abnormalities were found on the physical 
examinations of any of the women who participated in the trial. Three women in the 
granisetron group and 2 in the placebo group reported mild to moderate stress levels. 
The others had nothing recorded on Axis IV. None of the women in either group had a 
Global Assessment of Functioning (GAF) score rated by the investigator as being less 
than 80 on Axis V. The mean ± SD GAF score was 92.50 ± 2.89 for the granisetron 
group and 87.00 ± 6.71 for the placebo group. 
 
The mean period in remission ± SD of Axis I disorders in months was 7.00 ± 3.46 in 
the granisetron group and 4.8 ± 2.77 in the placebo group. For the granisetron group 
the mean number of previous episodes was 4.00 ± 4.08 and for the placebo group 4.40 
± 5.18. The mean duration of psychiatric illness in years was 8.75 ± 5.06 for 
granisetron and 9.40 ± 5.37 for placebo. 
 
All the participants receiving granisetron were on antidepressant treatment with 
citalopram, although one of those subjects was receiving nefazodone in combination 
with citalopram. In the placebo group there were 3 participants on citalopram, 3 on 
fluoxetine and 1 on sertraline. One of those patients on citalopram was also being 
treated with topiramate. The mean dose in citalopram equivalents was 45.00 ± 12.91 
mg for granisetron and 30.00 ± 10.95 mg for placebo. The average duration on current 
treatment in months was 5.25 ± 1.71 for granisetron and 11.57 ± 12.46 for placebo. 
 
In the granisetron group, 2 patients were on medication other the oral contraceptive 
pill, 1 on two agents (amiloretic and quertran powder) and the other on just diotroxil. 
In the placebo group there were 4 subjects on other medication, 1 on spirolina, 1 on 
acuretic, 1 on clonazepam and 1 on eltroxin, caltrate plus and gluroplex. In terms of 
contraception, 3 participants were using an oral contraceptive pill, 1 had undergone a 
tubal ligation and 1 participant in the granisetron group was post-menopausal and was 
not using any method of contraception or hormone replacement therapy. In the 
placebo group, 3 participants were on oral contraceptives, 2 were using condoms, 1 
had an intra-uterine device and 1 participant was not using any contaception before 
the trial as her partner had had a vasectomy. 
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The mean duration of sexual dysfunction in months was 12.25 ± 8.73 for granisetron 
and 7.71 ± 6.40 for placebo. When asked to describe the specific symptoms of their 
sexual dysfunction as part of the semi-structured interview one woman in both the 
granisetron and 2 in the placebo group complained of impairments in all phases of the 
sexual response cycle. Eleven women complained of a loss of desire and interest in 
sex (the single exception being in the placebo group). Ten women reported difficulties 
with orgasm (1 in each group did not). The most common presentation of sexual 
dysfunction in these women was a combination of lack of desire and difficulties with 
orgasm (6 in total). Only 4 woman complained of a lack of arousal (2 in the 
granisetron group and 2 in the placebo group), and this was always in combination 
with a disturbance of at least one other phase of the sexual response cycle. 
 
There were no statistically significant differences in any of these clinical variables 
between the 2 groups. 
 
3.3 Mini-International Neuropsychiatric Interview 
 
The MINI confirmed the clinical diagnosis made according to DSM-IV criteria in all 
cases. In all cases the primary diagnosis was major depressive disorder in remission. 
Other secondary diagnoses made on the MINI corresponded with those made 
clinically according to DSM-IV criteria. 
 
3.4 Clinical Global Impression Scale 
 
None of the participants that participated in the study experienced any significant 
change in their clinical condition as evidenced by their CGI severity and global 
improvement scores over the 2-week trial period. The mean total change in CGI 
severity score ± SD was 0.00 ± 0.00 for the granisetron group and 0.00 ± 0.00 for the 
placebo group. The mean total change in CGI global improvement score ± SD was 
0.30 ± 0.50 for the granisetron group and 0.00 ± 0.00 for the placebo group. 
 
There was no significant difference between the CGI severity scores of the 
granisetron and placebo group at baseline. The mean ± SD CGI severity score at 
baseline was 1.00 ± 0.00 for the granisetron group and 1.2 ± 0.4 for the placebo 
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group. There was no significant difference between the CGI severity scores of the 
granisetron and placebo group at endpoint either. The mean ± SD CGI severity score 
at baseline was 1.00 ± 0.00 for the granisetron group and 1.20 ± 0.40 for the placebo 
group. The CGI global improvement scores at endpoint were also not significantly 
different between the granisetron and placebo groups. The mean ± SD CGI global 
improvement scores at endpoint were 3.80 ± 0.50 in the granisetron group and 3.70 ± 
0.80 in the placebo group.  
 
3.5 Rating scales of sexual dysfunction 
 
3.5.1 Arizona Sexual Experience Scale 
 
On individual items of the Arizona Sexual Experience Scale the following proportion 
of the 12 participants rated their symptoms of sexual dysfunction as being of moderate 
or greater severity. Nine (75%), interest in sex, ability to get aroused or excited and 
ability to achieve orgasm, and 10 (83%), overall sexual satisfaction. 
 
There was no statistically significant difference between the two groups on the mean 
± SD baseline total scores of the Arizona Sexual Experience Scale (granisetron group 
25.0 ± 3.8; placebo 19.6 ± 9.5). At baseline the total scores ranged from 20 to 28 for 
the granisetron group and 18 to 30 for the placebo group. All 5 participants in the 
granisetron group and 6 of the 7 subjects in the placebo group had a score of 5 or 
greater on at least one item of the Arizona Sexual Experience Scale at baseline. At the 
endpoint the mean scores between the two groups were also not statistically different 
on this scale (granisetron 20.3 ± 9.7; placebo 12.4 ± 6.5; p=0.497). The total scores 
for both groups at the Baseline, Week 1 and Week 2 assessments are illustrated 
graphically in Figure 3.1. 
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Figure 3.1 Total scores for the Arizona Sexual Experience Scale (at Baseline, 
Week 1 and Week 2 assessments) 
 
 
 
The change in total scores from baseline to endpoint represents an 18.8% reduction 
(25.0 to 20.3) for the granisetron group and a 36.7% reduction (19.6 to 12.4) for the 
placebo group. There was also no statistically significant difference between the 
granisetron group (4.8 ± 7.6) and placebo group (7.1 ± 7.4) in terms of the overall 
change in total scores over the 2 weeks of the trial. When sub-analyses were 
performed on the individual items of the Arizona Sexual Experience Scale no 
significant differences were present on any of these sub-scales. 
 
Descriptive statistics for the change from baseline to endpoint for both the individual 
items and the total scores are detailed in Table 3.1. This data is presented graphically 
in Figure 3.2. 
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Table 3.1 Descriptive statistics for the Arizona Sexual Experience Scale 
(M indicates Mean, SD indicates Standard Deviation) 
 
 
  
Placebo 
 
 
Granisetron 
 
Item Baseline Week 1 Week 2 Total 
change 
Baseline Week 1 Week 2 Total 
change 
 M SD M SD M SD M SD M SD M SD M SD M SD 
1 4.4 1.5 2.9 1.9 2.9 1.7 1.6 1.5 5.5 1.0 5.3 1.0 4.3 2.4 1.3 2.5 
2 4.6 1.4 3.0 2.0 2.9 1.7 1.7 1.5 4.8 1.5 4.3 2.1 4.3 2.4 0.5 1.0 
3 4.9 1.5 3.3 2.1 3.4 1.9 1.4 1.8 4.8 1.9 4.8 1.5 3.8 2.6 1.0 2.0 
4 4.6 1.0 3.1 1.6 3.6 1.3 1.1 1.5 5.8 0.5 5.5 0.6 4.3 2.1 1.5 1.9 
5 4.5 1.2 2.8 0.8 2.8 0.8 1.4 1.6 4.3 0.5 4.0 0.0 3.8 0.5 0.5 0.6 
Total 19.6 9.5 12.0 6.8 12.4 6.5 7.1 7.4 25.0 3.8 23.8 4.9 20.3 9.7 4.8 7.6 
 
 
 
 
 
Figure 3.2 Individual items and total change in score at endpoint for the Arizona 
Sexual Experience Scale 
 
 
 
0
1
2
3
4
5
6
7
8
Ite
m
 1
Ite
m
 2
Ite
m
 3
Ite
m
 4
Ite
m
 5
To
ta
l
Placebo
Granisetron
 66
3.5.2 Feiger Sexual Function and Satisfaction Questionnaire 
 
On individual items of the Feiger Sexual Function and Satisfaction Questionnaire the 
following proportion of patients rated their sexual dysfunction as being of moderate or 
greater than moderate severity. Six (50%), enjoyment of sex; 11 (91%), overall 
satisfaction with sex; 8 (66%), difficulty achieving orgasm; 6 (50%), inability to 
achieve orgasm; 9 (75%), satisfaction with ability to achieve orgasm and satisfaction 
with intensity of orgasm. 
 
There was no statistically significant difference between the two groups on the mean 
baseline scores of the Feiger Sexual Function and Satisfaction Questionnaire 
(granisetron 23.0 ± 4.6; placebo 20.1 ± 4.9). At the endpoint the mean scores between 
the two groups were also not statistically different on this scale (granisetron 18.0 ± 
6.8; placebo 16.4, ± 5.1; p=0.703). The total scores for both groups at the Baseline, 
Week 1 and Week 2 assessments are illustrated graphically in Figure 3.3. 
 
Figure 3.3 Total scores for the Feiger Sexual Function and Satisfaction 
Questionnaire (at Baseline, Week 1 and Week 2 assessments) 
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The change in total scores from baseline to endpoint represents a 21.7 reduction (23.0 
to 18.0) for the granisetron group and a 18.4% reduction (20.1 to 16.4) for the placebo 
group. There was also no statistically significant difference between the granisetron 
group (5.0 ± 7.6) and placebo group (5.1 ± 7.2) in terms of the overall change in total 
scores over the 2-weeks of the trial. When sub-analyses were performed on the 
individual items of the Feiger Sexual Function and Satisfaction Questionnaire no 
significant differences were present on any of these sub-scales. 
 
Descriptive statistics for the change from baseline to endpoint for both the individual 
items and the total scores are detailed in Table 3.2 and this data is presented 
graphically in Figure 3.4. 
 
 
Table 3.2 Descriptive statistics for the Feiger Sexual Function and Satisfaction 
Questionnaire (M indicates mean, SD indicates standard deviation) 
 
 
  
Placebo 
 
Granisetron 
 
Item Baseline Week 1 Week 2 Total 
change 
Baseline Week 1 Week 2 Total 
change 
 M SD M SD M SD M SD M SD M SD M SD M SD 
1 2.4 0.8 2.1 0.7 1.9 0.7 0.6 0.8 3.8 0.5 3.3 1.0 3.3 1.0 0.5 1.0 
2 4.1 0.9 3.1 1.1 3.1 1.1 1.0 1.0 5.0 0.0 5.0 0.0 4.3 1.0 0.8 1.0 
3 4.0 1.4 3.0 1.9 3.4 1.7 0.6 1.4 3.3 2.1 3.0 1.8 2.3 1.9 1.0 2.0 
4 3.0 1.9 2.3 1.9 2.6 1.7 0.4 1.5 3.3 2.1 3.0 1.8 2.3 1.9 1.0 2.0 
5 3.3 1.3 2.7 1.3 2.7 1.3 0.6 1.0 3.8 0.5 3.5 1.0 3.0 1.2 0.8 1.0 
6 3.3 1.3 2.7 1.3 2.7 1.3 0.6 1.0 4.0 0.0 3.8 1.5 3.0 1.2 1.0 1.2 
Total 20.1 4.9 16.0 5.1 16.4 5.1 5.1 7.2 23.0 4.4 21.5 4.6 18.0 6.8 5.0 7.6 
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3.6 Discontinuations and adverse events 
 
Other than the two discontinuations which took place after randomisation but before 
trial medication was commenced there were no further discontinuations during the 
course of the trial. With regard to treatment emergent adverse events, 3 participants in 
the granisetron group reported headaches, 2 reported constipation and 1 reported 
experiencing fatigue. In the placebo group 2 participants reported headaches and 1 
developed a breast blister during the two-week period of the trial. They were all 
described as being of mild severity and in no instance required treatment or 
discontinuation from the trial. No serious adverse events were reported. There was no 
statistically significant difference in terms of adverse events between the 2 groups. 
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Figure 3.4 Individual items and total change in score at endpoint for 
the Feiger Sexual Function and Satisfaction Questionnaire 
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4.0 DISCUSSION AND CONCLUSIONS 
 
4.1 Introduction and summary 
 
Sexual dysfunction is a common side effect of treatment of serotonergic 
antidepressants. The problem has a significant impact on a patient’s quality of life and 
compliance with medication. Given the often long-term nature of depressive and 
anxiety disorders this obviously has important implications for the prognosis and 
successful management of these conditions. 
 
This report began by describing the human sexual response cycle and summarising 
the neurobiological and psychosocial factors that underlie normal sexual function. It 
then gave an overview of sexual dysfunction generally, sexual dysfunction associated 
with depression and sexual dysfunction dysfunction associated with antidepressant 
treatment. The management of AISD was discussed with an emphasis on the 
biological interventions that are more relevant in the context if this report. It was 
necessary to describe the trial drug, granisetron, in some detail because its mechanism 
of action (selective 5HT3 antagonism) is central to the rationale for this study.  
 
The hypothesis of the study was that granisetron would prove to be an efficacious 
augmentation strategy for AISD when investigated under randomised double blind 
placebo controlled conditions. This hypothesis was based on current thinking at the 
time that AISD was caused by increased serotonergic activity at 5HT2 and 5HT3 
receptors. 
 
The methods and materials of the study were described and the results of primary and 
secondary measures reported on. The results of this study were negative in that they 
did not find granisetron to have efficacy for this indication. 
 
Although the study sample was small and may well have failed to detect a significant 
difference when in reality a difference was present (a type-2 error), its findings are in 
keeping with other recent literature. Current thinking favours the role of the 5HT2 
receptor over the 5HT3 receptor in the pathogenesis of AISD.  
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4.2 Interpretation and relevance of findings 
 
4.2.1 Recruitment and randomisation 
 
Recruitment to the study proved much more difficult than had been anticipated. Forty 
women were screened and approached for their informed consent to participate. 
Ultimately, only twelve were randomised into the trial. The most common reason 
given for not participating was related to the inconvenience of attending the 
assessments. In addition, a large number of woman who at first appeared suitable for 
the study were prevented from participating because of one or other of the exclusion 
criteria. The most troublesome exclusion criteria were those requiring the onset of the 
sexual dysfunction to be temporally related to commencing the antidepressant and the 
requirement that there had been no change in their medication over the preceding two 
months. The vast majority of women screened were determined to be unsuitable 
before they were approached to sign written informed consent, but a small number 
who were otherwise both suitable and willing refused to participate when asked to 
sign the informed consent form. The reason given for this was that although they were 
willing to try an experimental medication, they felt intimidated by signing a legal 
document. 
 
Of the 12 women who were randomised into the trial 5 were randomised to the 
granisetron group and 7 to the placebo group. This difference in numbers arose 
because of the small sample size and the random allocation of subjects to either the 
granisetron or placebo groups. The 2 premature discontinuations were due to a change 
in their personal circumstances or problems unrelated to the study itself. 
 
4.2.2 Demographic and clinical variables 
 
The granisetron and placebo groups were well matched in that there were no 
significant differences between their demographic variables at baseline. The sample 
was homogenous in that all participants were female. The variation in mean age 
(43.25 ± 16.82 versus 33.00 ± 5.29 years), although not significant, may have 
introduced some bias given that age is a significant factor determining what is 
considered normal sexual function. It was important to control for the fact that all 
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participants were either married or involved in a long-term relationship. In order for 
the instruments to detect changes in sexual function during the 2-week period of the 
trial the subjects needed to have the opportunity to engage in sexual activity. 
Employment status was reported in that it was a further indicator of the wellbeing or 
functional intactness of the sample group. 
 
Clinical variables were also well matched with no significant differences between the 
granisetron and placebo groups at baseline.  
 
Although participants were always likely to be in remission because of the inclusion 
criteria, the finding that all 12 of them had a diagnosis of major depressive disorder 
was somewhat surprising. The relative lack of comorbid anxiety disorders was also 
unexpected. The use of the MINI in this study validated the clinical diagnosis made 
by the investigator. Beyond the clinical interview and MINI no formal assessment of 
personality was completed. If, based on that, the finding that only 1 subject in the 
granisetron group and 1 subject in the placebo group had significant personality 
disorder traits, then the undetected presence of personality factors may have 
introduced a sample bias. Personality is clearly intimately involved in the individual’s 
expression of sexuality and sexual behaviour. 
 
Although there was not any statistical difference in terms of medical comorbidity it is 
possible in a sample of this size that the presence of even stable medical conditions 
could have introduced a bias. The participant in the granisetron group with multiple 
cardiovascular risk factors is of particular concern because of the impact of these 
factors on sexual functioning. Similarly, the woman in the placebo group with 
possible temporal lobe epilepsy may have had a medical reason that accounted for her 
sexual dysfunction. Epilepsy is known to impact on sexual function. The fact that no 
significant abnormalities were found on the physical examinations of any of the 
women who participated in the trial supports the contention that they were a generally 
healthy sample. 
 
The relatively low prevalence of stress reported (5 participants in total reported mild 
to moderate stress levels) was somewhat surprising. This was most likely associated 
with the fact that as a group they were, by all indications other than sexual 
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functioning, stable and well. This was reflected by their GAF scores which were all 
80 or above and had a mean ± SD of 92.50 ± 2.89 for the granisetron group and 87.00 
± 6.71 for the placebo group. 
 
The mean period in remission and the mean duration of psychiatric illness in years 
was similar for both groups. However, the mean number of previous episodes varied 
more widely in the placebo group, partially as a result of the higher number of 
participants and small sample (n=7 versus n=5). 
 
The fact that all the participants receiving granisetron were on antidepressant 
treatment with citalopram whereas in the placebo group the antidepressant agent 
varied more widely may have introduced a bias in spite of the statistical difference not 
being significant. Different SSRI’s are associated with different reported rates of 
sexual problems, but these differences are probably not clinically significant. Of more 
concern was the patient on a combination of citalopram with topiramate for possible 
temporal lobe epilepsy and the participant who was receiving nefazodone in 
combination with citalopram. The nefazodone had been used (successfully) to 
augment a partial response of the patient’s depressive symptoms to citalopram; it was 
not being used as an augmentation strategy for AISD though it is possible that it may 
have had a beneficial effect on these side effects before entry into the study. The fact 
that sexual dysfunction was experienced whilst taking nefazodone would tend to 
suggest this was not significant. The mean dose in citalopram equivalents (45.00 ± 
12.91 mg for granisetron and 30.00 ± 10.95 mg for placebo) and the average duration 
on current treatment (5.25 ± 1.71 months for granisetron and 11.57 ± 12.46 months 
for placebo) varied between the 2 groups. Although this was not significantly different 
it is thought that the incidence of AISD rises with the antidepressant dose. 
 
The concurrent use of non-psychiatric medications by women participating in the trial 
is noted, although the impact of those agents on sexual function is not clear. The use 
of these medications was evenly distributed between the two groups (2 participants on 
3 agents in the granisetron group and 4 participants on 7 agents in the placebo group). 
However, although quantitatively there was not a statistical difference, qualitatively it 
was difficult to control for the differential effects of these drugs. Both the oral 
contraceptive pill and menopause have been associated with hormonal changes that 
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can effect sexual functioning. It is therefore possible that this was a confounding 
factor in the 3 participants on oral contraception and the 1 participant who was post-
menopausal in the granisetron group, and the 3 participants on oral contraception in 
the placebo group. This was, however, a difficult variable to control for given the 
requirements of ethical research and the problems with recruitment. Each woman’s 
position in the menstrual cycle was unfortunately not asked or recorded. There is 
significant evidence to suggest that the different phases of the sexual response cycle 
vary according to stage in the menstrual cycle. 
 
The mean duration of sexual dysfunction (12.25 ± 8.73 months for granisetron and 
7.71 ± 6.40 months for placebo) was longer than the mean duration on current 
treatment (5.25 ± 1.71 months for granisetron and 11.57 ± 12.46 months for placebo). 
This would appear to contradict the exclusion criterion that taking the serotonergic 
antidepressant should predate the onset of sexual dysfunction; in other words it 
suggests that there was not a causal link between the two. In reality this statistic is an 
artefact caused by the way the question about duration on current treatment was 
phrased in the semi-structured interview done at baseline. This variable refers 
specifically to the duration on current dose and drug. In fact, every individual in the 
sample had been on a lower or higher dose of the same antidepressant well before the 
onset of sexual side effects.  
 
The specific symptoms of sexual dysfunction that the participants reported as part of 
the semi-structured interview were in keeping with that reflected in the literature. 
Three women had impairments in all phases of the sexual response cycle, eleven 
complained of a loss of desire and interest in sex and 10 woman reported difficulties 
with orgasm. The most common presentation of sexual dysfunction in these women 
was a combination of lack of desire and difficulties with orgasm while only 4 women 
complained of a lack of arousal that was always in combination with a disturbance of 
at least one other phase. This is again in keeping with current literature. 
 
In accordance with the study protocol and inclusion and exclusion criteria, all 
participants had a CGI severity score of 2 or less. The granisetron and placebo group 
were also well matched at baseline in terms of the degree of severity or remission of 
their Axis 1 disorder. The finding that there was no change in CGI severity scores 
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between baseline and endpoint confirmed that there was no change in the subjects’ 
clinical condition during the trial period. This was confirmed by the CGI global 
improvement scores that were not significantly different between either baseline and 
endpoint or granisetron and placebo groups. Participation in the study did not 
therefore impact on the stability of the participants’ psychiatric disorder.   
 
4.2.3 Rating scales of sexual dysfunction 
 
The finding that on the Arizona Sexual Experience Scale 75% of participants rated 
their interest in sex, ability to get aroused and ability to achieve orgasm as being at 
least moderately impaired is in keeping with the information obtained in the semi-
structured interview and other literature on the subject. That 83% of them reported 
moderate or greater dissatisfaction with their overall sexual functioning is also 
significant. 
 
It is interesting that on the individual items of the Feiger Sexual Function and 
Satisfaction Questionnaire only half rated the impairment in their ability to enjoy sex 
as being moderate or worse. Moderate or greater difficulty achieving orgasm and 
complete anorgasmia were reported (66% and 50%), but significantly satisfaction 
with the ability to achieve orgasm and satisfaction with the intensity of orgasm (75%) 
were more common. As with the Arizona scale moderate or greater impairment in 
overall satisfaction with sex was a common complaint (91%). 
 
The lack of any statistically significant differences between the granisetron and 
placebo groups on the baseline total scores and baseline individual item scores of both 
rating scales indicates that the 2 groups were evenly matched in terms of the severity 
and range of their sexual dysfunction. The severity of sexual dysfunction reported in 
the sample met the requirements for the rating scales to be valid. 
 
The fact that overall change in total scores and the mean scores between the two 
groups at endpoint is not statistically different on either scale is the pivotal finding of 
this study. That sub-analyses performed on the individual items of both scales also 
failed to reveal significant differences is also important for two reasons. First, it 
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confirms the negative findings and secondly it excludes the possibility that granisetron 
was superior to placebo for a particular subtype of sexual dysfunction. 
 
On the Feiger scale the reduction from 21.7% (23.0 to 18.0) for granisetron compared 
with the 18.40% (20.1 to 16.4) reduction for placebo hints at a weak trend towards the 
superiority of granisetron. However, the 18.8% (25.0 to 20.3) reduction in total scores 
of the granisetron group compared to the 36.7% (19.6 to 12.4) reduction for the 
placebo group from baseline to endpoint represents a vivid illustration of the failure of 
granisetron to show efficacy on the Arizona scale. These results are likely to be a 
function of the small sample size and a considerable placebo effect. This would be in 
keeping with research on depressed patients and sexual dysfunction; marked placebo 
responses are a frequent finding in these studies. 
 
4.2.4 Discontinuations and adverse events 
 
As discussed earlier there were two discontinuations after the participants had been 
randomised. There is, however, no question of these discontinuations being due to 
granisetron as neither of them had commenced trial medication at the time that 
personal circumstances caused them to withdraw their consent. There were no further 
withdrawals once medication had been started. 
 
The adverse events and new side effects reported in both the granisetron and placebo 
groups were considered by the participants to be of mild severity. Headaches and 
constipation are recognised as potential side effects of treatment with granisetron. In 
this study the 3 participants who reported headaches, the 2 that reported constipation 
and the 1 who reported fatigue in the treatment group may well have experienced side 
effects that were causally related to granisetron. However, the incidence of these 
complaints was not statistically different to that in the placebo group, possibly 
because of the small sample size. The breast blister experienced by 1 patient in the 
placebo group did not appear to be related to participation in the trial. No serious 
adverse events were reported 
 
It therefore seems that both granisetron and placebo were safe and well tolerated 
within the context of this study. This finding is in keeping with existing data on 
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granisetron and its benign side effect profile probably lowers the threshold of 
clinicians for using an adjunctive strategy of doubtful efficacy. 
 
4.3 Strengths and limitations 
 
The strengths of this study lie in its design. Randomised, double blind, placebo 
controlled trials are considered to deliver the highest level of evidence. The scientific 
reasoning behind the study and its experimental methodology were sound. At the time 
this project was conceived the problem of AISD was extremely topical and the 
deficiency of evidence-based data in the area widely acknowledged. The study was 
both relevant and conducted according to high ethical standards. This study highlights 
an unfortunate lack of knowledge regarding the pathogenesis of AISD, as well as the 
urgent need for better treatment options. 
 
The most serious shortcoming of the study relates to its small sample size and 
consequently the weakened power of the statistical analysis. A sample of 12 subjects 
is inadequate to base any definitive conclusions on and the likelihood of a type-2 error 
is high. However, whilst the study would certainly have been stronger if there had 
been more participants, its negative outcome is in keeping with other similar negative 
studies and with current thinking around the relative roles of the 5HT2 and 5HT3 
receptors.  
 
In retrospect it may have been unwise to restrict participation to only female subjects. 
Although this restriction simplified the assessment of gender specific sexual 
dysfunction and averted the use of different rating scales for men and woman, the cost 
of a homogenous sample was that it unfortunately halved the number of potential 
subjects available for recruitment. The net result of this was that the difficulties with 
recruitment and the small sample size offset the gains made in terms of being able to 
generalise the result to all females with AISD. Attempts to extend recruitment to a 
number of private practice settings also met with limited success. Interestingly, during 
the course of recruiting to this study it appeared that men were far more likely to 
complain about their sexual difficulties and express an interest in participating than 
were woman. 
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It is possible that the 2-week duration of the trial was too short a period for 
statistically significant differences to emerge between the treatment and placebo 
groups. Unfortunately, the length of the trial was restricted to a certain extent by 
financial constraints and the cost of the trial medication involved. Furthermore, a 
previous open label study which suggested that granisetron was of benefit in AISD 
did so when the agent was used not only for less than 2 weeks but also when it was 
used on an as required basis. 
 
Another potential problem common to many studies of this nature is that it may not 
have adequately controlled for certain unavoidable confounding variables. For 
example, although participants with pre-existing sexual dysfunction were excluded 
from the study, this piece of information relied solely on the subject’s recollection and 
subjective report. It would have been very difficult to quantify and hence control for 
any number of other potentially confounding psychosocial variables. However, given 
that psychological and social factors are inevitably also determinants of sexual 
functioning, the study should have perhaps taken greater cognisance of each 
individual subject’s personality structure and current life and relationship 
circumstances. It is quite possible in a sample this small that these factors could have 
affected the measured improvements in sexual function. 
 
4.4 Conclusions and recommendations 
 
The results of this study do not support the use of granisetron as an adjunctive strategy 
for the treatment of AISD in women taking serotonergic antidepressants. Furthermore, 
the results of this trial do not support a primary role for the 5HT3 receptor in the 
aetiology of AISD. 
 
It has not been conclusively proven that granisetron has no usefulness in the treatment 
of AISD. Anecdotal reports of positive responses to adjunctive treatment of AISD 
with granisetron continue to arise from time to time. However, anecdotal reports are 
often conflicting, and that is after all the reason why such matters are tested in 
randomised placebo controlled trials. The outcomes of several admittedly limited 
studies of this nature have not supported the efficacy of granisetron for this indication. 
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Furthermore, although a role for the 5HT3 receptor has not been conclusively 
excluded, the focus of research subsequent to the initiation of this study has shifted 
away from the 5HT3 receptor. It appears that the 5HT2 receptor is a much more 
plausible mediator of the sexual dysfunction caused by antidepressants with 
serotonergic activity. Perhaps the strongest indication of the role of the 5HT2 receptor 
is provided the newer antidepressants mirtazepine and nefazodone which have a much 
lower incidence of sexual dysfunction associated with their use. Both of these agents 
have strong antagonistic activity at the 5HT2 receptor. 
 
Although a definitive randomised study that addresses the limitations of this and other 
similar work would be desirable to conclusively discount the usefulness of granisetron 
and the role of the 5HT3 receptor, the weight of evidence does not suggest this should 
be a priority. It is likely that solutions to the problem of AISD and theories as to their 
cause lie elsewhere. Further research should aim to further clarify the role of the 5HT2 
receptor and its subtypes, possibly using selective 5HT2 receptor antagonists in 
randomised double blind placebo controlled conditions. The emphasis of further 
research in this area will probably look more closely at the development of new 
generation antidepressants with highly selective receptor activity and a lower 
association with sexual problems. As is the case with the sexual dysfunction 
associated with depression, sexual dysfunction generally and even normal sexual 
functioning, AISD is probably related to not only multiple pharmacological and 
physiological factors, but to a myriad of psychosocial factors too.  
 
It should be stressed that clinicians are still not screening adequately for and assessing 
AISD. Furthermore, they are a long way from having a comprehensive range of 
effective evidence-based management options for the problem. The area is most 
definitely still worthy of further research as the problem represents a major obstacle to 
the effective treatment of anxiety disorders and depressive illnesses. The impact of 
sexual dysfunction on the quality of life of patients taking antidepressants and their 
families cannot easily be quantified and should not be underestimated. 
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 APPENDIX A Information and Consent Form 
 
INFORMATION AND CONSENT FORM 
 
A double blind placebo controlled study of granisetron in antidepressant induced 
sexual dysfunction. 
 
My name is Dr Sean Jespersen. I am a psychiatrist from the Department of Psychiatry 
at the University of the Witwatersrand. This study is a research project on people who 
develop sexual side effects while they are being treated with antidepressants. 
Currently, there are no widely accepted treatments for this problem. The sexual side 
effects of antidepressants include diminished sex-drive and difficulty attaining 
orgasm. I would be most grateful for your participation in this study. 
 
Taking part in the study involves you taking one tablet a day for two weeks. The 
tablet that you receive may be either granisetron (Kytril) or a dummy medication (a 
placebo). Neither you nor I will know which you are taking. You will be asked to visit 
me three times during the course of the two-week period you are involved in the 
study. 
 
Kytril is a medication registered for the treatment of nausea and vomiting. It is 
considered safe and has few side effects of its own. The most common side effects are 
headache and constipation. There is reason to believe that Kytril may relieve the 
problems with sexual functioning that are associated with taking antidepressants. It 
blocks a particular type of receptor in the brain that is thought to be a part of the 
reason why antidepressants cause sexual side effects. 
 
The aim of the study is to better understand antidepressant induced sexual dysfunction 
and to develop better treatments for the problem. Your participation in the study is 
voluntary and you are free to refuse to participate or withdraw your consent at any 
time. If you refuse to participate you will not be disadvantaged in any way. The 
results of the study will be strictly confidential and only your initials and study 
number will be used. There will be no costs to you to participate. 
 
Your help with the project is much appreciated. 
 
Please sign below to acknowledge that you consent to participate in the study having 
read the INFORMATION AND CONSENT FORM and having understood the 
implications of your participation. 
 
Signature of participant: 
 
Name:        Date: 
 
Signature of witness: 
 
Name:        Date: 
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APPENDIX B Initial Assessment Form 
 
INITIAL ASSESSMENT FORM    Date: 
 
1. Demographic data 
Initials:    Kit / study number: 
Age:     Gender: 
 
Marital status:    Employment: 
 
2. Multi-axial diagnosis 
 
Axis I: 
 
 
Axis II: 
 
Axis III: 
 
 
Axis IV: 
 
Axis V: 
 
3. Psychiatric history 
Period in remission: 
 
Number of previous episodes: 
 
Duration of psychiatric illness 
 
4. Medication 
Current psychiatric medication: 
 
 
Duration on current psychiatric medication: 
 
Other current medication: 
 
 
Allergies: 
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5. Sexual history 
 
Symptoms of sexual dysfunction: 
 
 
Duration of sexual dysfunction: 
 
Contraception: 
 
6. Physical examination 
 
 
 
 
 
 
 
 
 
 
 
 
 
7. Exclusion criteria (exclude participant if any of the following are “NO”) 
Written informed consent has been signed: YES / NO 
 
The subject is able to give informed consent and comply with the protocol: YES / NO 
 
The woman is on contraception: YES / NO 
 
There has been no change of psychotropic medication in the last 2 months: YES / NO 
 
CGI score is 1 or 2: YES / NO 
 
Any comorbid Axis I disorder is in remission: YES / NO 
 
Any medical illness is stable: YES / NO 
 
There is no history of cardiac disease: YES / NO  
 
The sexual dysfunction is temporally related to the antidepressant: YES / NO 
 
 
 
 
 
 
 
Signed:       Date: 
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APPENDIX C Clinical Global Impression Scale 
 
  
CLINICAL GLOBAL IMPRESSION SCALE 
 
 
Severity of Illness 
To be completed at Visits 1, 2 and 3. Record the 
participant’s response in the appropriate column. 
 
 
Visit 1 
Baseline 
Day 0 
 
 
Visit 2 
Week 1 
Day 7 
 
Visit 3 
Week 2 
Day 14 
 
1. Normal, not at all mentally ill 
 
2. Borderline mentally ill 
 
3. Mildly mentally ill 
 
4. Moderately mentally ill 
 
5. Markedly mentally ill 
 
6. Severely mentally ill 
 
7. Among the most severely mentally ill 
   
 
Global Improvement 
To be completed at Visits 2 and 3. Record the 
participant’s response in the appropriate column. 
 
 
Visit 1 
Baseline 
Day 0 
 
 
Visit 2 
Week 1 
Day 7 
 
Visit 3 
Week 2 
Day 14 
 
1. Very much improved 
 
2. Much improved 
 
3. Minimally improved 
 
4. No change 
 
5. Minimally worse 
 
6. Much worse 
 
7. Very much worse 
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APPENDIX D Arizona Sexual Experience Scale 
 
 
ARIZONA SEXUAL EXPERIENCE SCALE 
(FEMALES) 
 
 
To be completed at Visit 1, 2 and 3. Record the 
participant’s response in the appropriate column. 
 
Visit 1 
Baseline 
Day 0 
 
Visit 2 
Week 1 
Day 7 
 
Visit 3 
Week 2 
Day 14 
How has your interest in sex been over the past week? 
1 = Greater than normal 
2 = Normal 
3 = Minimally diminished 
4 = Moderately diminished 
5 = Markedly diminished 
6 = Totally absent 
   
How has your ability to get sexually aroused or excited been 
over the past week? 
1 = Greater than normal 
2 = Normal 
3 = Minimally diminished 
4 = Moderately diminished 
5 = Markedly diminished 
6 = Totally absent 
   
How has your ability to achieve orgasm been over the past 
week? 
1 = Greater than normal 
2 = Normal 
3 = Minimally diminished 
4 = Moderately diminished 
5 = Markedly diminished 
6 = Totally absent 
   
How would you rate your overall sexual satisfaction? 
1 = Greater than normal 
2 = Normal 
3 = Minimally diminished 
4 = Moderately diminished 
5 = Markedly diminished 
6 = Totally absent 
   
How would you rate your overall improvement since your 
last medication change? 
1 = Very much improved 
2 = Much improved 
3 = Minimally improved 
4 = Unchanged 
5 = Minimally worse 
6 = Much worse 
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APPENDIX E Feiger Sexual Function and Satisfaction Questionnaire 
 
 
FEIGER SEXUAL FUNCTION AND SATISFACTION QUESTIONNAIRE 
(FEMALES) 
 
 
To be completed at Visit 1, 2 and 3. Record the 
participant’s response in the appropriate column. 
 
Visit 1 
Baseline 
Day 0 
 
Visit 1 
Week 1 
Day 7 
 
Visit 1 
Week 2 
Day14 
How would you describe your ability to enjoy sex during the 
past week? 
1 = Fully enjoyed 
2 = Sometimes enjoyed 
3 = Rarely enjoyed 
4 = Never enjoyed 
   
Overall, how satisfied were you with your sexual function 
during the past week? 
1 = Completely 
2 = Highly 
3 = Moderately 
4 = Slightly 
5 = Not at all 
   
How often did you have difficulty achieving orgasm during 
the past week? 
1 = Rarely or never 
2 = Occasionally 
3 = Frequently 
4 = Usually 
5 = Always 
   
How often were you unable to reach orgasm during the past 
week? 
1 = Rarely or never 
2 = Occasionally 
3 = Frequently 
4 = Usually 
5 = Always 
   
How satisfied were you with your ability to achieve orgasm 
during the past week? 
1 = Highly 
2 = Moderately 
3 = Slightly 
4 = Not at all 
   
How satisfied were you with the intensity of your orgasm 
during the past week? 
1 = Highly 
2 = Moderately 
3 = Slightly 
4 = Not at all 
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